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ACS – Acute coronary syndrome 
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FCA – Fibrous calcified atheroma 
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LAD – Left anterior descending artery 
LDL – Low density lipoprotein 
LME – Linear mixed model 
LQMM – Linear quantile mixed model 
MCP-1 – Monocyte chemoattractant protein-1 
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MMP – Matrix metalloproteinase 
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NOS – Nitric oxide synthase 
PCI – Percutaneous coronary intervention 
PIT – Pathological intimal thickening 
QCA – Quantitative coronary angiography 
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SUMMARY 
 
Background – Coronary artery disease (CAD) is the leading cause of death in the 
world. Total plasma homocysteine (tHcy) is an independent risk factor for 
CAD, and while tHcy is lowered by folic acid (FA)/vitamin B12 (B12) treatment 
– such therapy has failed to result in clinical benefit.  
 
Aim – Investigate the connection between treatment with FA/ B12 and progression of 
sub-clinical CAD in patients with stable angina pectoris (SAP) with invasive 
measurements of CAD progression and associated metabolic changes. 
 
Materials and methods – Patients included in Sub-group studies from the Western 
Norway B Vitamin Intervention Trial (WENBIT) undergoing percutaneous 
coronary intervention were randomized to daily treatment with FA/B12 or 
placebo. Coronary angiograms and quantitative coronary angiography (QCA) 
were obtained at baseline and follow-up along with virtual histology 
intravascular ultrasound. Plasma levels of asymmetric dimethylarginine 
(ADMA), trimethyllysine (TML) and monocyte chemoattractant protein-1 
(MCP-1) were collected. 
 
Results –Paper I demonstrated that treatment with FA/B12 was associated with a 
potential risk of rapid progression of CAD by QCA. Paper II showed that while 
FA/B12 did not affect levels of ADMA, TML or MCP-1, ADMA and TML 
predicted progression of CAD by QCA. In paper III MCP-1 was associated with 
unstable coronary plaques.  
 
Conclusion and implications –Vitamin B treatment showed a potential adverse effect 
on angiographic progression of CAD. While the methylated amino acids 
ADMA and TML adversely affected CAD – FA/B12 intervention did not affect 
either ADMA/TML levels or plaque stability as measured by VH-IVUS.  
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“There is a disorder of the breast, marked with strong and peculiar symptoms, 
considerable for the kind of danger belonging to it, and not extremely rare, of which I 
do not recollect any mention among medical authors. The seat of it, and sense of 
strangling and anxiety with which it is attended, may make it not improperly be called 
angina pectoris.” 
Heberden, W. 1772. Some account of a disorder of the breast. Medical Transactions. 
The Royal College of Physicians of London. 2: 59-67. 
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 INTRODUCTION 
Coronary artery disease (CAD) is a chronic, fibroproliferative inflammatory condition 
affecting the arterial walls of the epicardial vessels supplying the myocardium. 
Typically characterized by decades of clinically silent progressions, it is punctuated by 
sudden clinical events such as acute myocardial infarctions (AMI), unstable angina 
pectoris (UAP) or sudden cardiovascular death (SCD) associated with substantial 
morbidity and mortality1. 
 
1.1. Clinical entities 
The term angina pectoris refers to the subjective chest discomfort or pain experienced 
during myocardial ischemia2. It is often associated with shortness of breath, nausea or 
diaphoresis. Myocardial ischemia may occur secondary to obstructive CAD, but can 
also manifest itself due to other perturbations of myocardial oxygen metabolism such 
as anemia, hypoxemia, hypovolemia as well as other causes. 
 
Stable angina pectoris (SAP) is the clinical entity in which angina pectoris is triggered 
with exertion in a predicable manner and is relieved by rest or administration of 
nitroglycerine. When patients present with symptoms of angina which are either new 
in onset, last >20 minutes, occurs at rest or a previously sustainable level of physical 
activity or in the wake of a previous AMI, the episode should be considered an acute 
coronary syndrome (ACS)3, 4. Further sub-division into ST- and non-ST-elevation 
acute coronary syndrome (STEMI and NST-ACS respectively) is based upon the 
presence or absence of significant ST-elevations in the patient’s electrocardiogram3. 
Depending on whether the myocardial ischemia is sufficient to result in cellular 
necrosis and release of circulating cardiac markers (e.g. troponin T), the patient is 
diagnosed with either non-ST-elevation myocardial infarction (NSTEMI) or unstable 
angina pectoris (UAP)3. 
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1.2. Cardiovascular epidemiology 
In 2008 noncommunicable diseases (NCD) surpassed infectious disease as the leading 
cause of mortality with 63% of the world’s 57 million deaths5. Of these 36 million deaths 
17.3 million – or 30% of all global deaths – were due to cardiovascular disease (CVD), of 
which CAD was the most prevalent with 7.3 million5. While traditionally considered a 
disease of industrialized nations and the “Western” world, more than 80% of the world’s 
CVD deaths occur in middle- to low income countries5 – exalting a disproportional 
economic burden of chronic disease management on underdeveloped health care systems.  
 
Risk factors for developing CAD are mostly modifiable and an abnormal lipid profile, 
smoking, hypertension, diabetes, abdominal obesity, psychosocial factors, consumption 
of fruits, vegetables, limited amount of alcohol, and regular physical activity  account for 
90% of the population attributable risk of myocardial infarction (the last four associated 
with lower risk) worldwide regardless of region and gender6. Despite decreasing 
incidence and mortality of CAD in high-income countries7, 8, the worldwide prevalence 
continuous to increase6, 9. The prevalence of obesity, diabetes, and hypertension have 
risen steadily the last decades5, 10 reaching epidemic proportions – heralding further rise 
in CAD incidence and mortality rates. 
 
The reduction in cardiovascular mortality in high-income countries have been attributed 
to increased risk factor control and advances in disease management such as statin 
therapy, antithrombotic medication and revascularization procedures such as 
percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in 
patients with clinically unstable CAD11. However, despite these apparent advancements, 
patients with established CAD have a substantial residual risk for future mortality and 
morbidity. Of patients 45 years of age experiencing their first AMI 19% of men and 
26% of women will die within a year, increasing to 36% and 46% respectively after five 
years12. The rate of recurrence is substantial even in the younger part of the CVD 
demographic, patients aged 45 to 64 years, 15% of men and 22% of women experience a 
recurrent AMI or SCD within 5 years12. 
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1.3. Pathogenesis of atherosclerosis 
Disease processes affecting the arterial wall are termed arteriosclerosis, meaning 
‘hardening of the arteries’. The term atherosclerosis is a distinct form of 
arteriosclerosis caused by the presence of an atheroma within the arterial lining, 
originally stemming from the word atheroma (Gr. ਕșȒȡĮ), meaning gruel. The 
atheroma is histopathologically an accumulation of soft yellowish material composed 
of macrophages, extracellular cholesterol deposits and necrotic tissue. Atherosclerosis 
can affect several parts of the arterial vasculature, including coronary as well as 
cerebral and peripheral arteries, causing conditions such AMI, stroke and claudication. 
CAD is the clinical entity where atherosclerosis affects the coronary arteries, causing 
symptoms when it compromises the myocardial blood supply1.  
 
Evidence suggests that coronary atherosclerosis begins as early as the first and second 
decade of life13, 14. Necropsy studies reveal atherosclerotic lesions in 2% of men 15-19 
years of age, rising to 19% in 30-34 year old men15. Intracoronary ultrasound 
investigations reveal atherosclerotic coronary lesions in 17% in patients less than 20 
years of age undergoing coronary angiography prior to heart transplantation and is 
related to coronary risk factors16.  
 
1.4. Histology 
Several attempts have been made to characterize the different coronary atherosclerotic 
lesions, notably the American Heart Association (AHA) lesion classification system17, 
18. The AHA classification was subsequently modified by Virmani et al.19 and is used 
in this thesis along with a statement report on terminology by the same authors20. 
Table 1.  Modified AHA classification based on Morphological description.
Lesion Abbreviation Description 
Nonatherosclerotic intimal lesions 
Intimal thickening IT 
The normal accumulation of smooth muscle cells (SMCs) in the 
intima in the absence of lipid or macrophage foam cells. 
Intimal xanthoma 
(previously "fatty streak") IX 
Luminal accumulation of foam cells without a necrotic core or 
fibrous cap. Based on animal and human data, such lesions 
usually regress. 
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The modified AHA classification19 is based on morphological description and includes 
7 categories; intimal xanthoma, intimal thickening, pathological intimal thickening, 
fibrous cap atheroma, thin fibrous cap atheroma, calcified nodule and fibrocalcific 
plaque as illustrated in table 1. This classification focuses on morphologically 
recognizable histological patterns and reflects the understanding that atherosclerosis is 
a dynamic process with multiple stages not necessarily succeeding each other in a 
linear manner.  
 
1.4.1. Intimal xanthoma and intimal thickening. 
 Intimal xanthoma (IX), previously named “fatty streaks”, are focal accumulations of 
lipid-laden macrophages (termed “foam-cells”) occurring at specific branch points 
throughout the coronary vasculature beginning soon after birth19. However, current 
evidence suggests that IXs are not the substrate of progression to more complex 
coronary lesions, since they both demonstrate the ability to regress and are differently 
distributed in children than in the adult population13, 15, 21. Intimal thickening (IT) on 
the other hand occurs at sites associated with atherosclerotic lesions in the adult21 and 
is generally thought to be the precursor of advanced coronary lesions19. ITs are intimal 
masses consisting of smooth muscle cells (SMCs), usually clonal22 expansions, and 
proteoglycan-collagen matrix with little or no infiltrating inflammatory cells. 
 
Pathological intimal thickening PIT 
SMCs in a proteoglycan-rich matrix with areas of extracellular 
lipid accumulation without necrosis. 
Fibrous cap atheroma FCA Well-formed necrotic core with an overlying fibrous cap. 
Thin fibrous cap atheroma TCFA 
A thin fibrous cap infiltrated by macrophages and lymphocytes 
with rare SMCs and an underlying necrotic core. 
Calcified nodule CN Eruptive nodular calcification with underlying fibrocalcific plaque. 
Fibrocalcific plaque FP 
Collagen-rich plaque with significant stenosis usually contains 
large areas of calcification with few inflammatory cells; a 
necrotic core. 
AHA, American Heart association; SMC, smooth muscle cells. Modified from Virmani R, Kolodgie FD, Burke AP, 
Farb A, Schwartz SM. Lessons from sudden coronary death : A comprehensive morphological classification 
scheme for atherosclerotic lesions. Arteriosclerosis, thrombosis, and vascular biology. 2000;20:1262-1275. 
Progressive atherosclerotic lesions
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1.4.2. Pathological intimal thickening. 
Pathological intimal thickening (PIT), an intermediate stage between IX/IT and the 
fibrous cap atheroma, is characterized by the presence of extracellular lipid 
accumulation typically adjacent to the media with and relative lack of SMCs18, 19, 23. 
Necrosis is absent, and subluminal macrophage and T lymphocyte infiltration in the 
intima overlying the lipid pool occurs18, 19, 23. 
 
1.4.3. Fibrous cap atheroma 
When a distinct “fibrous cap” of fibrous tissue overlies a lipid core of a certain size, 
the lesion is characterized as a fibrous cap atheroma (FCA)17, 19. This is generally 
considered the first of the advanced coronary lesions and is also known as a 
fibroatheroma. The lipid core initially consists of necrotic cellular debris, lipid-laden 
macrophages and a relative lack of extracellular matrix, while the fibrous cap is 
constituted by SMCs and collagen fibers and varying presence of macrophages and 
lymphocytes19. In more developed FCAs, the necrotic core enlarges, free cholesterol 
and cholesterol crystals becomes more abundant and separate necrotic cores 
consolidates as the proteoglycan-collagen matrix is depleted. 
 
1.4.4. Thin fibrous cap atheroma 
Further growth of the atheroma and thinning of the overlying fibrous cap is the 
hallmark of the thin cap fibroatheroma (TCFA) characterized by a fibrous cap of <65 
μm thick, typically devoid of SMCs but infiltrated by macrophages secreting matrix 
metalloproteinases (MMPs)19, 20, 24. TCFA are termed “vulnerable plaques” because 
they are the anatomical substrates of coronary plaque rupture19, 25-27. The underlying 
lipid core typically includes necrosis, calcification, neoangiogenesis (vasa vasorum) 
and hemorrhages. 
 
The cut-off at 65 μm is based on previous studies that show that the mean fibrous cap 
thickness of ruptured coronary plaques were 23±19 μm with 95% of caps <64 μm24. 
Since these measurements have been done in ex vivo specimens, they are potentially 
subject to fixation artifacts. In vivo measurements with more sensitive optical 
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coherence tomography (OCT) techniques shows that median (IQR) value of cap 
thickness in ruptured plaques was 54 (10) μm with 95% of the thinnest cap thickness 
<80 μm28. 
 
1.5. Progression of coronary atherosclerosis 
Progression of coronary atherosclerosis is linked to several factors of which endothelial 
dysfunction, inflammation, dyslipidemia, plaque rupture, intra-plaque hemorrhage and 
smoking have been established. Several other, less established mechanisms have been 
proposed and will be discussed later. The interaction between lipid metabolism and 
inflammation is shown in figure 1. 
 
1.5.1. Endothelial dysfunction and shear stress 
The epithelial monolayer lining the arterial wall is a metabolic active and regulatory 
important tissue. It is generally accepted that endothelial dysfunction, generally defined 
as impaired endothelial vasodilator function, is one of the first step in atherogenesis and 
is due to loss of endogenous nitric oxide production29. Evidence suggests that at least part 
of this effect is mediated through elevated levels of asymmetric dimethylarginine 
(ADMA) which is an endogenous nitric oxide synthase (NOS) inhibitor30, 31. 
 
Shear stress in vascular biology is defined as the coplanar force vector generated by the 
movement of blood along the vessel wall. Endothelial cells alter function in response to 
altered shear stress through mechanoreception32. Turbulent blood flow produces less 
shear stress than laminar and it is precisely in these regions of the arterial three – i.e. the 
inner side of curvatures, near branch points or the outer wall of bifurcations that 
atherosclerotic lesions tend to amass33. The role of mechanical, shear, stress in the 
initiation of the atherosclerotic process is substantial32. 
 
1.5.2. Inflammation 
The recognition of the inflammatory response as playing a pivotal role in the formation 
and progression of atherosclerosis has been one of the leading breakthroughs in the 
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understanding of the biology of atherosclerosis in recent years. Research has shown 
relationships with both progression of CAD, plaque instability and rupture, as well as 
with clinical end-points in numerous studies with different biomarkers. High-sensitivity 
C-reactive protein (hsCRP) has already earned its mark as an independent biomarker34 of 
risk and several other inflammatory markers are under investigation.  
 
Activated endothelial cells express surface antigens which facilitates the transmigration 
of inflammatory cells such as monocytes. Once adherent to the endothelium, monocytes 
are drawn into the plaque along concentration gradients of chemokines, such as monocyte 
chemoattractant protein-1 (MCP-1)35. These antigens, commonly known as adhesion 
molecules, are upregulated in settings of irritative endothelial stimuli such as 
dyslipidemia, hypertension and hemodynamic alterations1. In addition, both T-cells 
(helper and regulatory) as well as B-cells, in a limited number, are present in the intima 
and probably regulates macrophage activity1.  
Figure 1. Overview of the intersection between inflammation and lipid metabolism in relation to 
the development of atherosclerotic lesions.  
Oxidized LDL (oxLDL) is engulfed my monocytes by scavenger receptors. Both transforming growth 
factor beta (TGF-ȕ) and interferon gamma (IFN-Ȗ) is involved. VLDL, very-low density lipoprotein; IL-10, 
interleukin-10; TLR2, Toll-like receptor 2: CETP, cholesteryl ester transfer protein. Adapted with 
permission from Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of 
atherosclerosis. Nature. 2011;473:317-325. Copyright © 2011, Rights Managed by Nature Publishing 
Group. 
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1.5.3. Dyslipidemia 
Dysregulation of lipid metabolism is paramount to the development of coronary 
atherosclerosis36. Consistently, elevated LDL cholesterol has shown a strong association 
with the development of atherosclerotic CVD, while high levels of HDL cholesterol is 
linked to favorable outcome. Hypertriglyceridemia is also related to increased risk of 
cardiovascular events, though not as definite as the association between triglycerides and 
other risk factors37, 38. 
 
It is believed that the retention of LDL particles within the intima is a necessary step in 
atherogenesis. Oxidation of these particles to OxLDL elicits inflammatory stimuli which 
are thought to be pivotal in the initiation of atherosclerotic progression. OxLDL interacts 
with scavenger receptors on the surfaces of recruited monocytes1. Upon OxLDL-
phagocytosis, these cells become lipid-laden and termed foam cells due to their 
characteristic appearance.  
 
1.5.4. Intra-plaque hemorrhage and plaque rupture  
It has more recently been appreciated that the expansion of the necrotic core is heavily 
dependent on both intra-plaque hemorrhage and plaque rupture 25. A significant portion 
of free cholesterol in the necrotic core of the atherosclerotic plaques stems from the 
cellular membrane of erythrocytes1. Intra-plaque hemorrhage probably occurs from 
disruption of weak vasa vasorum which has grown into the plaque from the adventitia as 
a response to central plaque hypoxia39. 
 
Disruption of the fibrous plaque with subsequent plaque rupture and atherothrombosis 
does not necessarily result in luminal obstruction and clinical events. In fact, most plaque 
ruptures are clinically silent25, 26 and heal without precipitating any symptoms at all. 
Evidence of atherothrombosis, tissue organization and re-endothelialization are present in 
most atherosclerotic lesions above 50% diameter stenosis, and only about 11% of plaque 
ruptures are “virgin” without sign of previous ruptures40. While not leading to clinical 
20 
 
events, a silent plaque rupture does lead to significant expansions of the plaque volume, 
but development of obstructive coronary artery disease following repeat ruptures. 
 
1.5.5. Smoking 
Smoking is a major risk factor for cardiovascular mortality and morbidity6. It has been 
associated with both endothelial dysfunction and heightened thrombogenicity41, possibly 
mediated through increased inflammation42, oxidation of LDL-particles43 and impaired 
endothelial relaxation44. 
 
1.6. The unstable coronary plaque and acute coronary syndromes 
James E. Muller et al coined the phrase “the vulnerable plaque” in 1989 when referring to 
coronary plaques susceptible to rupture45. It is now widely acknowledged that such 
vulnerable plaques is the underlying histopathological feature in most ACS events and 
most, if not all, atherothrombotic events25. The common causal feature is disruption of 
the endothelial barrier between the blood and the highly thrombogenic material located 
within the coronary plaque. These plaques are seldom flow-limiting, angiographically 
significant stenoses, in fact as many as 75% of vulnerable lesions were identified in 
coronary segments with <50% diameter stenosis26, 46. Disruption of this endothelial 
barrier can manifest itself through different mechanism, either a plaque rupture, plaque 
erosion or a calcified nodule27. In 59 – 75% of ACSs, the event is due to plaque rupture 
while plaque erosion accounts for 33 – 44%. Calcified nodules are the instigators in only 
a fraction of the cases, approximately 2-9%19, 25. Depending on the coronary location of 
the plaque rupture, the blood coagulability at the time of rupture, the size of the thrombus 
formed and degree of luminal obstruction induced the clinical symptoms range from 
asymptomatic through unstable angina, non-ST-/ST-elevation infarction and sudden 
cardiac death25.  
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As previously mentioned, the most prevalent clinical manifestation of plaque rupture is 
now considered to be nothing, i.e. asymptomatic. This results in negative plaque 
remodeling and increased luminal obstruction (as seen in figure 2, frame C) with 
progression of angina as a result, rather than acute clinical events. 
 
Figure 2. Histopathological images of TCFA lesions, all from patients with sudden 
cardiac death.  
A, example of intact TCFA with necrotic core (NC). B, TCFA with plaque rupture and 
non-obstructive thrombus. Yellow arrow marks site of fibrous cap disruption. C, 
evidence of repeat plaque rupture (black arrow) resulting in 80% luminal occlusion. 
Adapted with permission from Arbab-Zadeh, A et al. (2012). "Acute Coronary Events." 
Circulation 125(9): 1147-1156. © 2012 Wolters Kluwer Health. All rights reserved. 
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In recent years it has been increasingly apparent that such lesions are not satisfactorily 
diagnosed in clinical practice and there is a growing consensus that early detection and 
intensive treatment of such lesions are paramount in order to decrease the rate of 
“unexplained” coronary events in optimally treated patient populations47. 
Inflammatory activity leads to production of proteolytic enzymes that degrades 
extracellular matrix and structural integrity of the fibrous cap which is rendered more 
vulnerable to mechanical stress48. These MMPs are collagenases whose expression is 
induced by inflammatory mediators1, 48. Apoptosis of both macrophages and SMCs 
probably plays an important part in plaque destabilization49.  
 
1.7. Biomarkers and risk factors 
A biomarker is defined as a “characteristic that is objectively measured and evaluated 
as an indicator of normal biologic processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention”50. This in contrast to a risk factor, which is 
defined as a characteristic, condition or behavior which confers to the individual an 
increased risk of experiencing disease or injury.  In many instances, the difference can 
be subtle – e.g. whether elevated CRP is a biomarker of atherosclerosis or a risk factor, 
but most authorities requires a risk factor to have a proven, causal relationship with the 
disease state51. 
 
The two biomarkers studied in this thesis both act as an indicator of a pathogenic 
process, thereby being defined as a biomarker, while evidence also suggest that they 
are causally related to the development of CAD and represents risk factors. 
 
1.7.1. Monocyte chemoattractant protein-1 (MCP-1) 
Monocyte Chemoattractant Protein-1 (MCP-1), also known as Chemokine ligand [C-C 
motif] 2 (CCL2), is a potent chemokine involved in the recruitment of monocytes, 
dendritic cells and Th-cells52. MCP-1 is one of the most studied chemokines and is 
instrumental in the recruitment of monocytes from the blood stream into 
atherosclerotic plaques52. Early evidence showed that mice deficient in either MCP-1, 
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or the corresponding receptor on circulating monocytes (CCR2) were resistant to the 
development of atherosclerosis35 implying that it is a condicio sine qua non in 
atherogenesis53.  
 
In basic research, MCP-1 has been linked to macrophage activity in atherosclerotic 
plaques54-56 and has shown to be associated with coronary risk factors in sub-clinical 
atherosclerosis57. In vivo studies reveals that MCP-1 predict restenosis following both 
balloon-angioplasty58 and stent implementation59. Clinical studies implies that it is a 
predictor of CVD mortality in middle-aged obese patients60. While some studies have 
found lack of association61, this has mainly been in apparently healthy subjects62. 
Genotype-studies are contradictory62, 63.  
 
Most interesting perhaps, is MCP-1s ability to independently predict cardiovascular 
events in an ACS setting, both in the acute64, 65 and chronic phase63, 64. MCP-1 has, as 
of yet, not been evaluated prospectively in the setting of SAP.  
 
1.7.2. Asymmetric dimethylarginine (ADMA) 
Endothelial function is intrinsically connected to nitric oxide (NO) production, and 
produced by NOS from L-arginine. Asymmetric dimethylarginine (ADMA) is a 
product of proteolytic degradation of methylated proteins and is a well-known 
competitive inhibitor of NOS associated with endothelial dysfunction and 
cardiovascular disease31. Plasma levels of ADMA have been associated with all-cause 
mortality in the general population30, acute coronary events in presumably healthy 
non-smokers66 as well as in patients with established CAD67. In addition, ADMA has 
been shown to be a endogenous inhibitor of endothelial progenitor cells68. In-stent 
restenosis has also been associated with ADMA levels69. While ADMA is produced 
through proteolysis, the regulation and relative importance of this process regarding 
plasma levels of ADMA has not been studied. Most data on predictors of ADMA 
levels pertains to mechanisms of degradation70.  
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1.7.3. Trimethyllysine (TML) 
Carnitine is necessary for the transport of long-chain fatty-acids into the mitochondria 
for beta-oxidation and can be obtained either by endogenous biosynthesis or dietary 
intake. Carnitine deficiency can result from either primary inborn errors of metabolism 
or from inadequate intake or impaired endogenous production secondary to other 
causes. The biosynthesis of carnitine starts with 6-N-trimethyllysine (TML). TML is 
the lysosomal or proteasomal degradation product of proteins containing trimethylated 
lysine residues such as histones71.  
 
Like ADMA, TML is produced through post-translational methylation of amino acids 
in nuclear and cytosolic proteins71 which is subsequently release through proteolysis; 
yet unlike for ADMA, associations of TML with CVD have not been previously 
addressed. In this context, it is interesting to note that both previous speculations 72 and 
emerging evidence73-75 suggest that epigenetic alterations  of chromatin is relevant to 
the development and progression of atherosclerosis. Accordingly we wanted to 
simultaneously investigate the association of circulation levels of both ADMA and 
TML with progression of CAD. 
 
1.6. Cardiovascular disease and homocysteine 
Hyperhomocysteinemia has been associated with CVD in several prospective studies76 
and a plethora of explanatory pathomechanisms have been proposed77-79. Interventional 
treatment with moderate to high doses of B-vitamins, including cobalamin (vitamin B12) 
and folic acid (vitamin B9), has been shown to lower total plasma homocysteine (tHcy) 
by supplying methyl groups for remethylation of homocysteine. While 20 years of 
intense homocysteine studies have culminated in several large scale clinical trials. The 
supposed beneficial effect on cardiovascular mortality by homocysteine-lowering folic 
acid supplementation has repeatedly failed to manifest itself78, 80-83.  
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Hyperhomocysteinemia has been associated with several risk factors for CVD which has 
primarily been explained by its putative atherothrombotic effect. Noteworthy, 
hyperhomocysteinemia results in upregulation of MCP-184 and it has been shown that 
folic acid supplementation alters the levels of MCP-1 in rats85. Interestingly, studies in 
humans have shown that the presence of obesity alters the direction of the correlation 
between MCP-1 and tHcy86. Hyperhomocysteinemia has several other atherothrombotic 
attributes such as upregulating interleukin-8 expression, increased SMC proliferation, 
increased collagen production, inhibition of thrombolytic mechanisms, free radical 
production, increased platelet reactivity, decreased degradation of ADMA and impaired 
endothelial function87-90. Even more intriguing, some consider hyperhomocysteinemia as 
a sign of impaired DNA-methylation, a crucial element in nuclear regulation and that it is 
through these mechanism that homocysteine is linked to disease91, 92. 
 
1.8. The dark side of folate metabolism 
The Western Norway B Vitamin Intervention Trial (WENBIT)93 and the Norwegian 
Vitamin Trial (NORVIT)94 were two large-scale clinical trials conducted in Norway. 
Neither trial showed any protective effect of intervention with B-vitamins in patients with 
established coronary heart disease. On the contrary, pooled analyses of these two trials 
done by our group showed a statistically significant increased risk of cancer incidence 
and all-cause mortality related to folic acid supplementation95. As of now there seems to 
be no upper limit to the amount of water-soluble vitamins recommended by international 
guidelines.  
 
A growing body of evidence has shown that both global and site-specific hypo- and 
hypermethylation of DNA and histones are associated with CVD73, 96. Some studies have 
shown that low folate intake are linked to DNA hypomethylation97, while high doses of 
FA induce aberrant DNA methylation in some98 but not all studies 99, 100. It has been 
speculated that the lack of cardiovascular protective effect of homocysteine-lowering FA 
supplementation is due to a simultaneously increased  methylation potential and 
subsequent epigenetic alterations of gene expression by folate 72. Histone methylation is 
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limited to the İ-amino groups of amino acid residues in the form of mono-, di- or 
trimethylation 73, and only two amino acids in histones undergo methylation, i.e. arginine 
and lysine 101, which may lead to the production of ADMA and TML, respectively. 
 
Though this area of epigenetic research has gained substantial interest during the last few 
years, many mechanisms have yet to be elucidated. It is not inherently obvious that 
excessive supplementation with water-soluble B-vitamins and folic acid to increase 
nuclear methylation capacity is uniformly positive and data suggest that there might be a 
“dark side” to folate metabolism. Whether disproportionate folic acid supplementation in 
certain sub-groups of patients could lead to excessive nuclear DNA methylation and 
increased risk of cardiovascular disease through alterations in genetic expression is not 
known, but biochemical inference might suggest so. 
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2. AIM AND HYPOTHESIS OF THE THESIS 
The main goal of the project was to investigate the connection between treatment with 
folic acid supplementation/vitamin B12 and progression of sub-clinical CAD in patients 
with stable angina pectoris (SAP) with invasive measurements of CAD progression and 
associated metabolic changes. 
 
Separate project aims 
2.1. Paper I: Investigate the effect of folic acid supplementation on progression of 
atherosclerosis in patients with SAP as measured by quantative coronary 
angiography (QCA)102. 
 
2.2. Paper II: Investigate whether the negative effect of folic acid supplementation 
observed in a sub-group of patients is related to increased plasma levels of the 
methylated amino acids ADMA and TML as well as assessing their ability to 
predict progression of coronary atherosclerosis as measured by QCA. 
 
2.3. Paper III: Study the effect of folic acid supplementation on the levels of MCP-1 
and consequently on the presence of TCFA as measured by IVUS. 
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“There are three kinds of lies: 
 lies, damned lies, and statistics.” 
 Quote attributed to Benjamin Disraeli (1804 – 1881). 
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3. MATERIALS AND METHODS 
3.1. Subjects 
The subjects included in the projects for the current thesis participated in the Western 
Norway B-vitamin intervention trial (WENBIT). This was a double-blinded, placebo-
controlled, 2-center trial that included 3,090 adult patients (20.5% women) who had 
undergone coronary angiography for suspected CAD. Of the 3,090 WENBIT 
participants, a total of 1,359 (44%) underwent PCI following the baseline angiogram. PCI 
was performed either as an elective procedure after a previous diagnostic angiography, 
immediately after the angiography or as a scheduled procedure at the 1 month follow-up. 
Of these 1,359 patients, 465 (34%) were treated at Stavanger University Hospital, 
Stavanger, and 894 (66%) at Haukeland University Hospital, Bergen, Norway. 
 
The general WENBIT exclusion criteria were an inability or reluctance to attend long-
term follow-up, alcohol abuse, mental illness, and known active malignant disease. 
For the sub-studies in the current thesis, patients at high risk of procedural complications 
or who presented with a baseline coronary anatomy of such a nature that repeat 
angiography would probably prove unsuccessful were also excluded.  
 
All WENBIT participants provided written informed consent, and the patients scheduled 
for repeat angiography provided additional written informed consent. The Regional 
Committee for Medical and Health Research Ethics, the Norwegian Medicines Agency, 
and the Data Inspectorate approved the WENBIT. The Regional Ethics Committee 
approved the protocol for the present sub-study. The ClinicalTrials.gov identifier was 
NCT00354081.  
 
3.1.1. WENBIT re-angiography sub-study (WENBIT-RA) 
A proportion of the patients undergoing PCI at WENBIT baseline were recruited into a 
pre-planned sub study (WENBIT re-angiography sub-study, WENBIT-RA) with serial 
angiography consisting of a planned repeat coronary angiography at approximately 1 year 
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of follow-up in the main WENBIT-trial for the evaluation of progression (or regression) 
of coronary atherosclerosis in non-treated segments by QCA. The patients eligible for 
this sub-study analysis were recruited from the Haukeland University Hospital from 
October 2001 to May 2004, from a total of 570 patients undergoing PCI at WENBIT-
baseline during this time period. The patients asked to participate largely constituted the 
primary referral population, so as to make scheduled repeat angiography practically 
possible. The follow-up repeat angiogram was either scheduled to occur approximately 
10 months after the initial PCI (to coincide with the 1-year WENBIT control group), or it 
was performed for clinical indications 90 days after the PCI. The patients scheduled for 
repeat angiography who were re-hospitalized for clinical indications within 90 days after 
the initial PCI were excluded to rule out complications related to baseline PCI (n = 13). 
 
3.1.2. Paper I and II study subjects: quantitative coronary angiography 
For paper I and II we used data from repeat coronary angiography to evaluate 
progression of angiographic CAD. Both baseline and follow-up coronary angiograms 
were analyzed using quantitative coronary angiography (QCA) in order to identify 
atherosclerotic lesions in non-intervened vessels and estimate progression during 
follow-up. In addition to general WENBIT and WENBIT-RA exclusion criteria, we 
here excluded patients with baseline and/or follow-up coronary angiograms considered 
unsuitable for quantitative analysis. 
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Figure 4. Flow chart of patients from WENBIT, through sub-studies and the 
corresponding papers in the thesis.  
WENBIT, western Norway B-vitamin intervention trial; PCI, percutaneous coronary 
intervention; HUS, Haukeland University Hospital;  
SUS, Stavanger University Hospital; QCA, quantitative coronary angiography; IVUS, 
intravascular ultrasound; VH, virtual histology. 
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3.1.3. Paper III study subjects: virtual histology 
Of the 371 patients undergoing their second coronary angiography in WENBIT-RA, 
231 had intravascular ultrasound (IVUS) performed in non-intervened vessels. Of 
these 231, a cohort 105 patients were also included in the global virtual histology-
IVUS (VH-IVUS) registry and IVUS-data was transferred to an external core lab for 
virtual histology analysis. All study participants were recruited from a subset of 
patients who after PCI at WENBIT baseline had been scheduled for re-angiography 
after one year. 
 
3.2. Primary end-points 
Analysis of coronary atherosclerosis progression was done using quantitative coronary 
angiography (QCA) for paper I and II, while presence of vulnerable plaques was assessed 
using VH-IVUS for paper III.  
 
3.2.1. Quantitative coronary angiography (paper I and II) 
The coronary plaque lesions for paper I and II were analyzed using digitalized QCA 
software (Quantcor QCA, CAAS II, version 5.0, Pie Medical Imaging, Maastricht, The 
Netherlands). An end-diastolic frame showing the stenosis without foreshortening or 
vessel overlaps and free of intracoronary guidewires was selected. If the stenosis differed 
in severity on different projections, the projection demonstrating the most severe stenosis 
was subject to analysis.  
 
The baseline and follow-up coronary angiograms were analyzed by 2 trained technicians 
who were unaware of the treatment regimen and who were supervised by an experienced 
interventional cardiologist. A total of 16 coronary artery segments were evaluated in all 
patients (i.e., 15 segments according to the American Heart Association standardization 
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criteria103  as shown in figure 5 plus the right atrioventricular branch). Eligible lesions for 
analysis had a reference diameter of 2 mm, a diameter reduction of 30% at baseline or 
follow-up, and were adequately visualized at similar projections on both angiograms. The 
analyzed segment had not been treated with PCI. Cases of disagreement between the 
observers about the eligibility of a certain lesion were subject to reanalysis by both 
observers. After all QCA procedures, segments from both observers were compared to 
ensure equality concerning the accurate numbering of the segments, the correct 
angiogram analyzed, and the actual stenosis portrayed.  
 
 
 
 
 
 
 
 
The contrast-filled tip of the catheter was used for calibration, and computer-defined 
obstruction analysis without manual contour correction was used, where applicable. 
However, ostial stenoses required the use of manually defined obstruction analysis (user-
defined reference vessel diameter and stenosis length), and branched artery segment 
required manual correction of vessel contour.  
Figure5.SegmentsofthecoronaryarteriesasdefinedbytheAmericanHeartAssociation.
AC,atrialcircumflexbranch;AM,acutemarginalbranch;AV,atrioͲventricularnodebranch;CB,conusbranch;
Circ,Circumflexartery;D1,firstdiagonalbranch;D2,seconddiagonalbranch;MainLCA,mainleftcoronary
artery;OM,obtusemarginalbranch;PD,posteriordescendingartery;PL,posterolateralbranch;RCA,right
coronaryartery;RPD,rightposteriordescendingartery;SN,sinusnodebranch;V,rightventricularbranch.
ReproducedfromAustenWG,EdwardsJE,FryeRL,etal.Areportingsystemonpatientsevaluatedfor
coronaryarterydisease.ReportoftheAdHocCommitteeforGradingofCoronaryArteryDisease,Councilon
CardiovascularSurgery,AmericanHeartAssociation.Circulation.1975;51:5Ͳ40,withpermissionofthe
AmericanHeartAssociation.
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The primary measures for each selected lesion were the minimum lumen diameter 
(MLD)104, 105 and diameter stenosis (DS)104, 105 for paper I and DS for paper II. Both 
parameters were measured as continuous variables, defined as the mean of the values 
measured separately by each observer. 
 
When all baseline and follow-up lesions had been analyzed by both observers, the 
interobserver difference in DS was calculated. The 10% of lesions with the largest 
difference were subject to reanalysis. DS was chosen as the appropriate variable to 
assess, because it, in contrast to MLD, is a relative measurement, thus reducing any 
potential calibration errors between the baseline and follow-up angiograms.  
 
For paper I, we additionally defined a post hoc secondary end-point of rapidly 
progressing lesions as the 25% of all analyzed lesions with the greatest diameter 
reduction expressed by DS as a categorical yes/no variable. 
 
Figure 6. Example of quantitative coronary angiography (QCA). 
The left image pane shows a stenosis of the right coronary artery (AHA segment 2) with a minimum 
lumen diameter (MLD) of 1.93 mm (47% diameter stenosis [DS]). The right image pane shows the 
stenosis at follow-up (approximately 10 months), now with a MLD of 1.63 mm and a corresponding DS of 
55%. Image acquired from Quantcor QCA, CAAS II, version 5.0, Pie Medical Imaging, Maastricht, The 
Netherlands. 
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3.2.2. Intravascular ultrasound and virtual histology (paper III) 
One of the most developed technology applicable for in vivo identification of TCFA is 
spectral analysis of IVUS radio frequency data106 called Virtual Histology-IVUS-(VH-
IVUS). With this technique, Virtual Histology Thin-Cap Fibroatheroma (VH-TCFA) is 
defined as a lipid rich atheromatous lesion with a thin overlying fibrous cap. These 
lesions have shown to be the most common cause of thromboembolic cardiovascular 
events27, 107, 108. VH-TCFA also predicts clinical events in a prospective study109. 
 
IVUS is a technique in which a miniaturized ultrasonic transducer in the 10-40 MHz 
range is introduced intracoronary in order to visualize the coronary arterial wall. VH-
IVUS is based on the spectral analysis of raw backscattered ultrasound data. VH-IVUS 
renders four different histological tissue components, namely fibrous, fibro-fatty, necrotic 
core and calcified, all with high correlation with histopathology in ex vivo validation 
studies106, 107, 110. Each of these neointimal components are presented as total volume 
(mm3) and percentage volume of total neointimal lesional volume.  
 
VH-IVUS data on the 105 patients included in the analyses in paper III were performed 
by the same interventional cardiologist after intracoronary administration of nitroglycerin 
0.2 mg. A 20 MHz, 2.9Fr IVUS catheter (Eagle Eye, Volcano Corp., Rancho Cordova, 
California) was advanced beyond the selected segment, and a motorized transducer 
pullback (0.5 mm/s) was performed. VH-IVUS data was lost in three patients due to 
corrupted data on disc, i.e. 102 patients had complete VH-IVUS data.  
 
All IVUS-data were transferred to the Global VH-IVUS Registry core lab for analyses 
using the pcVH 2.2 software (Volcano corp., Brussels, Belgium). This is a validated 
method for visualizing plaque morphology in vivo. An IVUS-lesion is defined as 
being present when the plaque burden (plaque volume / external elastic membrane 
volume) exceeds 40% over three consecutive frames. A VH-TCFA lesion was present 
when a necrotic core rich (>10% of cross-sectional area) element was identified in at 
least 3 consecutive frames as previously described109, 111. While pull-back was done in 
a per-vessel manner, data from the core lab was provided in a per-lesion form. For the 
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following analyses we aggregated VH-TCFA to patient-level – i.e. VH-TCFA status 
was reported per patient. 
 
 
 
3.3. Blood samples 
For papesr I and II blood samples were collected at baseline and follow-up before 
repeat angiography, corresponding to WENBIT study visits. Routine blood analyses 
such as hematologic parameters, renal function markers and lipid-related factors were 
analyzed in fresh samples at the Laboratory of Clinical Biochemistry, Haukeland 
University Hospital, using standard methods, all blinded to study end-points and 
randomization.  Blood samples for the measurements of total plasma homocysteine 
(tHcy), ADMA and B-vitamers were analyzed at the laboratory of Bevital AS, Bergen, 
Norway (www.bevital.no), using previously described methods112. Plasma TML, free 
carnitine and Ȗ-butyrobetaine were analysed using tandem mass spectrometry as 
described previously113 with some modifications of the high-performance liquid 
chromatography (HPLC) conditions. Estimation of glomerular filtration (eGFR) rate 
was done using the simplified Modification of Diet in Renal Disease (MDRD)-
equation114. 
Figure 7. Grayscale IVUS and Virtual Histology of TCFA. 
A thin cap fibroatheroma (asterix) in the proximal left anterior descending coronary artery of one of 
the study patients. The left panel shows an intravascular ultrasound radiofrequency image which is 
subsequently used to make the virtual histology image in the right panel. Green is fibrous tissue, 
yellow is fibro-fatty, red is necrotic core and white is calcified tissue. 
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For paper III, additional measurements of MCP-1 were analyzed at the Department of 
Clinical Science in collaboration with the Lipid Research Group, University of 
Bergen, Norway, using BioPlex® 200 multiplex array (Bio-Rad Laboratories, 
Hercules, CA, US).  
 
3.4. Clinical end-points 
Subjects analyzed in paper III were followed from the VH-IVUS study inclusion date 
for approximately 2 years. The follow-up endpoint was defined as a composite of fatal 
and non-fatal AMI. All events were adjudicated by the WENBIT-endpoint committee, 
unbeknownst of the MCP-1 serum levels and VH-TCFA status of the patient. 
 
3.5. Statistical methods 
3.5.1. General considerations and baseline characteristics 
For descriptive data mean (standard deviation [SD]) or median (interquartile range 
[IQR]) was used. Since most biological parameters are almost invariably skewed, median 
(IQR) was applied more often for biochemical data. 
 
Dissimilarities in baseline characteristics of continuous variables between subject groups 
in the different analyses such as TCFA versus non-TCFA in paper III or folic 
acid/vitamin B12 versus no folic acid/vitamin B12 in paper II were analyzed with either 
Welch two-sample t-test or chi-square/Fisher’s exact test with minimum likelihood where 
appropriate (i.e. cell number count <5) for categorical data. For some skewed variables 
logarithmic transformation were in some instances applied in order to approximate 
normal distribution. Back-transformation was consequently used for data presentation. 
Alternatively the non-parametric Mann-Whitney U test was applied. In paper I where 
four intervention groups were compared, differences in continuous variables between 
groups were investigated using analysis of variance (ANOVA).  
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A two-sided p-value of < 0.05 was considered statistically significant in all analyses. 
 
3.5.2. The fallacies of linear regression 
Linear regression has been the mainstay of medical statistics for several decades. 
However, several assumptions underlie the use of simple linear regression which are 
often violated in its application on biological data115. Simple linear regression fitted using 
the least squares method generally assumes: 
x Normality of data. I.e. normality of the residuals at each value of X or Y. More 
often than not biological or chemical data is skewed, zero-inflated or combinations 
thereof.    
x Homogeneity. I.e. the variance of the data should be the same at each value of X. 
Violation of this is referred to as heterogeneity or heteroscedasticity e.g. if body-
mass index has a higher spread in men than females or when serum potassium has 
a higher variance in patients with lower than higher glomerular filtration rate. 
x Fixed explanatory variables. Also called weak exogeneity. I.e. that the predictor 
variable X can be treated as a fixed – as opposed to a random – variable. 
Essentially assuming that the measured variable X is error-free.  
x Independence. Violation of error independence is one of the most serious 
problems and occurs if the Y value at Xi is influenced by other Xi. Both temporal 
and spatial correlation is more prevalent than one might guess. E.g. patients 
sampled from the same area may share genetic attributes that influence the way in 
which a certain biomarker varies between individuals.  
x Linearity. The response variable is a linear combination of the regression 
coefficients of the explanatory variables. E.g. the U-shaped relationship between 
body-mass index and mortality is a violation of this assumption116.  
Investigating these assumptions can be exhaustive and several pitfalls exist when one 
wishes to generalize findings from a sample estimate. In our dataset, several of these 
assumptions were violated and more advanced techniques were applied accordingly. 
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3.5.3. Loss of independence and mixed effects modeling  
Violating the assumption of independence could potentially severely affect statistical 
models and renders both p-values and estimates invalid115. Data with a nested or 
hierarchical structure results in pseudoreplication – e.g. multiple samples from the same 
individual.  
 
A mixed model is a statistical model which allows for both fixed and random effects. 
Fixed effects are explanatory variables that consists of non-random quantities – i.e. the 
levels of the variable included contains all possible levels (or all levels of interest), e.g. 
gender which would include both male and female. If the levels of a given variable are 
drawn at random from a population of more possible levels – i.e. study site in a 
randomized controlled trial. To generalize, if the effect of the levels of a factor could be 
drawn from a distribution of probability of such effects, the effect is random. While one 
is interested in the difference of the mean between fixed effects, it is the variance of 
means across the levels which are of interest regarding random factors. This can be used 
in a hierarchical structure where random effect is set to an identifier from which multiple 
samples are drawn – e.g. multiple measurements from the same patient. 
 
In both paper I and paper II repeated measures (“pseudoreplication”) was present. The 
treatment effect on the primary end-points was associated with up to seven coronary 
artery segments for each patient. Accordingly, linear mixed effects models fitted by 
restricted maximum likelihood were applied. The mixed effects model included a random 
effect term adjusting for the within-patient clustering of coronary artery segments. The 
models were computed with the software package R (The R Foundation of Statistical 
Science, Vienna, Austria) using Pinheiro and Bates’ referential implementation117 in the 
R package nlme118. 
 
3.5.4. Non-linear applications 
Non-linear relationships between explanatory and response variables are abundant in 
nature. In the organism the strong preservation of homeostasis in a given system almost 
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invariably implies that the effect a certain external stressor is altered when one reaches 
the outer boundaries of such a system. Thus, while the relationship between explanatory 
variables while be linear in a certain part of the distribution of Y, this is seldom the case 
when approaching the outer bounds.  
 
While it is possible to model non-linear relationships using a linear regression model with 
for example a second order polynomial function, one implicitly assumes the form of the 
relationship. Several solutions to this problem have been proposed, many relating to 
“smoothing” models pioneered by Hastie and Tibshirani119 with the introduction of 
generalized additive models (GAM). The additive model fits a smoothing curve through a 
scatterplot of the data without assuming a given relationship form. Several ways to 
estimate smoothers have been presented. Further work has been done by Wood120-122 
which resulted in the R-package mgcv. In our dataset we have used the mgcv package for 
the R software which uses the spline method described by Wood120. Generalized additive 
modelling in the mgcv package can be extended to generalized additive mixed effects 
models (GAMMs) which allow for spatial and temporal correlation in addition to 
hierarchical structuring of variance, and was used in paper II and III.  
 
GAM was applied in paper III for assessing the effect of folic acid supplementation on 
MCP-1, VH-TCFA presence and MI. In paper II GAMM was applied when we 
investigated the association between plasma levels of TML/ADMA and DS and 
subsequently discarded for a simpler method when a linear relationship was discovered. 
 
3.5.5. Conditional quantile regression 
While not an assumption per se, a limitation of linear regression is its (partial) ability 
to only predict the effect of the explanatory variables on the mean value of the 
outcome. While estimating the mean is often interesting, inference beyond the central 
tendency is not possible. Quantile regression as pioneered by Koenker and others123-125 
is a method to estimate the conditional quantile of a variable – i.e. to estimate the 
median value or any other part of the conditional distribution such as the 25th, 75th or 
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95th percentile. Quantile regression makes no assumption about the distribution at each 
value of the explanatory variable(s). Thus it is very robust to the presence of outliers in 
the dataset and needs no variance stabilizing variable transformation.  
 
Recently, the quantile regression method has been extended to allow for both fixed and 
random effects using a likelihood-based approach to estimate regression quantiles that 
uses the asymmetric Laplace distribution126. Application of this method is possible 
through the use of the lqmm package version 1.02127 for the R statistical software.  
 
In paper II a linear quantile mixed model approach using the lqmm package was 
applied to analyze the predictive value of ADMA and TML on progression of sub-
clinical atherosclerosis. This was done both to in order to account for outliers in the 
dataset and to visualize the relationship between the explanatory variables and all parts 
of the distribution of the outcome variable.  
 
Testing for relationships across the whole distribution in addition to the central 
tendency seems not to increase the rate of spurious findings. On the contrary, the 
presentation of several regression lines only helps to distinguish between spurious, 
asymmetrical and “real” relationships. The de facto result is a level of analytical 
transparency which only helps to expose all relationships in the dataset128.  
 
Asymmetrical effects are statistical associations which are more pronounced in a given 
part of an outcome variables distribution than others. E.g. the relationship between 
education and cardiovascular risk in women are more pronounced at higher than lower 
risk levels129. While principally different from non-linear modeling which inspects 
different parts of the explanatory variables distribution – the concept is cognitively 
translatable. In biological systems with a strong drive for homeostatic control, it would 
not be unreasonable to expect the effect estimates of a given predictor to differ when 
looking at the outer boundaries of the outcome parameters – i.e. when any 
compensatory mechanisms and the redundancy of the system are likely to have been 
exhausted. Quantile regression allows for this to be modeled.  
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“Alle Ding' sind Gift, und nichts ohn' Gift;  
allein die Dosis macht, daß ein Ding kein Gift ist 
[All things are poison, and nothing is without poison;  
only the dose permits something not to be poisonous]” 
 
Paracelcus (1493 – 1541). 
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4. RESULTS 
4.1. WENBIT study population 
All patient material is included from WENBIT which has been extensively described 
previously93. Briefly, the trial included 3090 patients referred to a diagnostic coronary 
angiography at either Haukeland or Stavanger University hospital during the time 
period of 1999-2004. A total of 3096 patients were randomized, six participants 
withdrew consent immediately after randomization without having started study 
medication and were excluded from further analyses. Consequently, the study 
population consisted of 3090 patients, of which 2121 (68.6%) were randomized at 
Haukeland University Hospital and 969 (31.4%) at Stavanger University Hospital. 
Clinical indications for referral to baseline angiography were SAP (n=2585 [83.7%]), 
ACS (n=461 [14.9%]) as well as aortic valve stenosis (n=44 [1.4%]).  
 
4.2. WENBIT-RA study-population (paper I and II) 
As previously stated, 348 patients had serial angiographic data available for QCA 
analysis. Baseline characteristics of these 348 patients are presented in table 2. Briefly, 
the mean age was 60.0 ± 10.2 years, 17.2% were women, and 31.3% of the patients 
had a previous history of AMI. The median serum total cholesterol level was 4.8 (IQR 
4.2 – 5.6) and serum C-reactive protein was 1.91 mg/L (IQR 0.87 – 5.14). Of the 348 
participants, a total of 96% were receiving statin treatment before PCI. No difference 
was found among the groups regarding dose or type of statin. The median plasma tHcy 
level was 10.0 ȝmol/L (IQR 8.1 – 11.0), serum folate was 10.6 nmol/L (IQR 7.7 – 
14.2), and 24 of the participants (6.9%) had hyperhomocysteinemia (>15.0 μmol/L). 
In table 4, the baseline characteristics for the 183 patients with angiographic findings 
who formed the basis of the statistical analyses in paper I and II are shown – i.e. 
patients with coronary lesions who qualified for QCA analysis according to the 
inclusion criteria (reference diameter of 2 mm, DS 30% at baseline or follow-up, 
adequately visualized at similar projections on both angiogram, segment untreated 
with PCI). For this group median (interquartile range [IQR]) age was 60.0 (14.0) 
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years, 15.8% were women and 27.3% of the patients had a history of prior myocardial 
infarction. Median (IQR) serum total cholesterol was 5.0 (1.3) mmol/L, serum 
triglycerides 1.54 (0.87) mmol/L and serum CRP 2.0 (4.9) g/L. 
 
Table 2. Characteristics and Laboratory Findings Among 348 Patients Successfully Studied with Quantitative Coronary 
Angiography at Baseline. 
Characteristics 
FA+B12+B6 FA+B12 B6 Placebo p -
Value (n= 91) (n= 87) (n= 87) (n= 83) 
Demographics and clinical 
characteristics 
Age (years) 59.2 ± 10.9 60.3 ± 10.6 59.7 ± 9.1 60.8 ± 10.1 0.76 
Female 14 (15.4%) 16 (18.4%) 16 (18.4%) 14 (16.9%) 0.94 
Systolic blood pressure (mm Hg) 138 ± 20 138 ± 19 142 ± 26 144 ± 25 0.19 
Body mass index (m2/kg) 27.1 ± 3.4 26.7 ± 3.3 26.8 ± 2.9 27.4 ± 3.8 0.46 
Ejection fractiona (%) 62.1 ± 8.7 64.0 ± 8.2 64.1 ± 8.1 65.1 ± 10.0 0.15 
Stable angina pectoris 66 (72.5%) 67 (77.0%) 61 (70.1%) 63 (75.9%) 0.72 
ACS 25 (27.5%) 20 (23.0%) 26 (29.9%) 20 (24.1%) 0.72 
Cardiovascular risk factors 
Extracardial vascular 
diseaseb 6 (6.6%) 10 (11.5%) 16 (18.4%) 9 (10.8%) 0.11 
Prior acute myocardial 
infarction 25 (27.5%) 29 (33.3%) 31 (35.6%) 24 (28.9%) 0.62 
Prior percutaneous coronary 
intervention 17 (18.7%) 19 (21.8%) 17 (19.5%) 13 (15.7%) 0.78 
Prior coronary bypass 6 (6.6%) 2 (2.3%) 2 (2.3%) 3 (3.6%) 0.47 
Hypercholesterolemiac 47 (51.6%) 51 (58.6%) 48 (55.2%) 52 (62.7%) 0.50 
Hypertensiond 36 (39.6%) 36 (41.4%) 35 (40.2%) 37 (44.6%) 0.91 
Diabetes mellituse 6 (6.6%) 9 (10.3%) 9 (10.3%) 9 (10.8%) 0.75 
Current smoker 29 (31.9%) 26 (29.9%) 28 (32.2%) 22 (26.5%) 0.84 
Extent of coronary artery 
disease 
One-vessel disease 46 (50.5%) 44 (50.6%) 43 (49.4%) 41 (49.4%) 1.00 
Two-vessel disease 32 (35.2%) 27 (31.0%) 32 (36.8%) 32 (38.6%) 0.76 
Three-vessel disease 13 (14.3%) 16 (18.4%) 12 (13.8%) 10 (12.0%) 0.69 
Medications 
Statins 91 (100%) 86 (98.9%) 84 (96.6%) 80 (96.4%) 0.22 
ȕ-adrenergic receptor 
antagonists 68 (74.7%) 74 (85.1%) 62 (71.3%) 62 (74.7%) 0.16 
Calcium antagonists 14 (15.4%) 14 (16.1%) 18 (20.7%) 10 (12.0%) 0.49 
ACE-inhibitors or ARB 14 (15.4%) 14 (16.1%) 16 (18.4%) 15 (18.1%) 0.94 
Acetylsalicylic acid 88 (96.7%) 86 (98.9%) 86 (98.9%) 83 (100%) 0.41 
ADP receptor antagonists 86 (94.5%) 81 (93.1%) 80 (92.0%) 79 (95.2%) 0.82 
Laboratory findings 
C-Reactive Protein (mg/L) 1.58 (0.82, 5.32) 2.01 (0.88, 4.91) 1.84 (0.99, 5.05) 2.16 (0.90, 5.53) 0.93 
S-LDL-cholesterol (mg/dl)f 108.3 (92.8, 131.5) 116.0 (92.8, 143.1) 
108.3 (92.8, 
131.5) 
123.7 (100.5, 
146.9) 0.25 
S-HDL-cholesterol (mg/dl)f 46.4 (38.7, 54.1) 46.4 (38.7, 54.1) 46.4 (38.7, 54.1) 46.4 (38.7, 58.0) 0.97 
S-creatinine (ȝmol/L) 86 (81, 95) 87 (82, 95) 91 (82, 99) 89 (82, 97) 0.46 
S-glucose (mmol/L) 5.8 (5.2, 6.8) 5.5 (5.0, 6.5) 5.6 (4.8, 6.6) 5.4 (5.0, 6.5) 0.63 
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P-total homocysteine (ȝmol/L) 9.79 (7.96, 11.75) 9.94 (8.72, 11.53) 9.22 (7.42, 11.21) 9.85 (7.73, 11.20) 0.13 
S-folate (nmol/L) 9.84 (7.52, 13.62) 9.78 (7.16, 14.7) 
10.63 (7.30, 
15.23) 10.56 (7.70, 10.56) 0.72 
Continuous variables are presented as mean±SD. Analysis of variance (ANOVA) was used to compare the 4 groups. For 
categorical variables, numbers and percentages are presented and a Chi square test used to compare the 4 groups. Fisher's 
exact test was used when appropriate. All biochemical parameters are presented as median (IQR). FA, folic acid (0.8 mg); B12, 
vitamin B12 (0.4 mg); B6, vitamin B6 (40 mg); ACE, Angiotensin I converting enzyme; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; ACS, composite syndrome consisting of acute coronary syndrome and both ST-elevated and non-ST-elevated 
myocardial infarction; S, serum; P, plasma. Percentages may not add up due to rounding of numbers. 
aEjection fraction was measured during ventriculography for the majority of the patients. When this was not performed, ultrasonic 
echocardiography was used. 
bA prior diagnosis of any peripheral or cerebrovascular disease. 
cDefined as a history of untreated total serum cholesterol 6.5 mmol/L or familial hypercholesterolemia. 
dDefined as systolic blood pressure > 140 and/or diastolic > 90 mmHg and/or antihypertensive therapy. 
eIncluding diabetes mellitus type I and II. 
fTo convert milligram per deciliter to millimole per liter, multiply by 0.02586. 
 
From the 348 patients undergoing PCI for CAD underwent QCA screening and were 
subject to the above mentioned QCA screening/inclusion criteria, only approximately 
half of the patients screened (183 vs. 348) had such lesions. Accordingly, the 
difference between these two groups is of particular interest, e.g. in regards to 
investigating selection bias. Table 3 illustrates the differences between those with 
(n=183) and those without (n=165) coronary lesions which fulfilled the QCA inclusion 
criteria and were subsequently including in the statistical analysis of the primary end-
points in paper I and II. However, it is important to note that although 165 patients did 
not have any lesions, they all had CAD and all received at least one coronary stent at 
baseline – i.e. established CAD. When comparing the two groups, patients with QCA-
analyzed stenoses had on average higher systolic blood pressure and had more 
extensive CAD, while other risk factors and clinical parameters where largely similar. 
The flow of patients from WENBIT into sub-studies is depicted in figure 4. 
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Table 3. Baseline Characteristics and Laboratory Findings in Patients eligible for quantitative coronary 
angiographya. 
Characteristics 
Group 1 (n=183) Group 2 (n=165) 
p-value 
QCA-eligble lesionsa No QCA-eligible lesionsa 
  
Demographic characteristics 
Age - years 60.3 (10.4) 59.6 (10.0) 0.53 
Female sex - no. (%) 29 (15.8) 31 (18.8) 0.56 
Intervention - no. (%) 
FA/B12/B6 49 (26.8) 42 (25.5) 0.87 
FA/B12 49 (26.8) 38 (23.0) 0.50 
B6 40 (21.9) 47 (28.8) 0.19 
Placebo 45 (24.6) 45 (27.3) 0.65 
Clinical characteristics 
Systolic Blood Pressure (mmHg) 142 (23) 137 (23) 0.03 
Body Mass Index (m2/kg) 27.1 (3.3) 26.9 (3.4) 0.53 
Ejection Fraction (%b) 63.5 (9.4) 63.6 (8.1) 0.86 
Cardiovascular risk factors - no. (%) 
ACS at presentation 57 (31.1) 50 (30.3) 0.86 
Prior AMI 50 (27.3) 59 (35.8) 0.09 
Prior PCI 34 (18.6) 32 (19.4) 0.85 
Prior CABG 6 (3.3) 7 (4.2) 0.64 
Hypercholesterolaemia 116 (63.4) 101 (61.2) 0.68 
Hypertension 80 (43.7) 64 (38.8) 0.35 
Diabetes Mellitus (type I and II) 17 (9.3) 16 (9.7) 0.90 
Current smoker 61 (33.3) 44 (26.7) 0.18 
Disease severity 
1-vessel disease 75 (41.0) 99 (60.0) <0.01 
2-vessel disease 73 (39.9) 50 (30.3) 0.08 
3-vessel disease 35 (19.1) 16 (9.7) 0.02 
Medical therapyc - no. (%) 
Statins 179 (97.8) 162 (98.2) 0.81 
ȕ-adrenergic receptor antagonists 139 (76.0) 127 (77.0) 0.82 
Calcium antagonists 29 (15.8) 27 (16.4) 0.90 
ACE-inhibitorsd 31 (16.9) 28 (17.0) 0.99 
Acetylsalisylic acid 181 (98.9) 162 (98.2) 0.57 
ADP receptor antagonists 171 (93.4) 155 (94.0) 0.85 
Laboratory findings 
S-C-Reactive Protein (mg/L) 2.0 (4.9) 1.8 (3.2) 0.11 
S-LDL cholesterol (mmol/L) 3.0 (1.3) 2.8 (1.1) 0.49 
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S-HDL cholesterol (mmol/L) 1.2 (0.4) 1.2 (0.4) 0.83 
S-creatinine (ȝmol/L) 88 (14) 88 (17) 0.41 
S-glucose (mmol/L) 5.6 (1.5) 5.6 (1.5) 0.59 
P-total homocysteine (ȝmol/L) 9.8 (3.1) 9.8 (3.5) 0.63 
P-folate (nmol/L) 10.3 (6.0) 9.8 (7.3) 0.11 
For continuous variables, median and interquartile range within each group is calculated. Mann-Whitney U-test 
was used to compare the two groups. For categorical variables, number and percentage is presented and a 
Chi square test was used to compare the four groups. Fisher's exact test was used when appropriate. FA, folic 
acid (0.8 mg); B12, vitamin B12 (0.4 mg); B6, vitamin B6 (40 mg); PCI, percutaneous coronary intervention; 
CABG, coronary artery bypass graft surgery; ACS, composite syndrome consisting of acute coronary 
syndrome including both ST-elevated and non-ST-elevated myocardial infarction; AMI, acute myocardial 
infarction; ACE, Angiotensin I converting enzyme; ADP, adenosine diphosphate; LDL, low-density lipoprotein; 
HDL, high-density lipoprotein Percentages may not add up due to rounding of numbers. 
aPatients who after QCA screening had coronary lesions which qualified for analysis with reference diameter of 
2 mm, a diameter reduction of 30% at baseline or follow-up, and were adequately visualized at similar 
projections on both angiograms. The analyzed segment had not been treated with PCI. 
bEjection fraction was measured during ventriculography for the majority of the patients. When this was not 
performed, ultrasonic echocardiography was used.  
cMedication at discharge.  
dIncluding ARB - angiotensin receptor blockers. 
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4.3. Effect of Homocysteine-Lowering B Vitamin Treatment on Angiographic 
Progression of Coronary Artery Disease: A Western Norway B Vitamin 
Intervention Trial (WENBIT) Substudy (Paper I) 
The American Journal of Cardiology. 2010;105:1577-1584. 
In this sub study of WENBIT, a total of 348 patients, (288 men) with a mean ± SD age 
of 60 ± 0.2 years, were available for serial QCA analysis after baseline coronary 
angiography. A total of 165 patients did not have any detectable lesions by QCA either 
at baseline or at follow-up. Among the remaining 183 patients, 309 coronary lesions 
were detected either at baseline or follow-up that fulfilled the angiographically defined 
inclusion criteria. The patients were followed up for a median of 10.5 months (25th -
75th percentile 9.2 – 11.8) for the assessment of CAD progression using QCA. The 
baseline tHcy levels were relatively low at 10.0 ± mol/L (25th -75th percentile 8.1 – 
11.0), but were still lowered by a mean of 22% in patients receiving folic acid/vitamin 
B12. At follow-up, we found 309 coronary QCA lesions with a significant decrease 
from baseline in the minimum lumen diameter of a mean of -0.16 ± 0.4 mm and an 
increase in the diameter stenosis of 4.4 ± 0.7%. However, while the group effect was 
luminal narrowing, some coronary segments actually showed regression of 
atherosclerotic obstruction as shown by an increase in MLD. Treatment with folic 
acid/vitamin B12 or vitamin B6 was not associated with a change in diameter stenosis 
or minimum lumen diameter. In a post hoc analysis, folic acid/vitamin B12 treatment 
was significantly associated with rapid progression (odds ratio 1.84, 95% C.I. 1.07 to 
3.18) defined as coronary segments which during follow-up had a change in diameter 
stenosis belonging to the 4th quartile of ǻDS. 
. In conclusion, vitamin B treatment showed no beneficial effect on the angiographic 
progression of coronary artery disease, and the post hoc analyses suggested that folic 
acid/vitamin B12 treatment might promote more rapid progression. Patients with such 
rapid stenosis progression were characterized by having more extensive lesions at 
baseline.  
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Table 4. Baseline Characteristics and Laboratory Findings in Patients with 
Angiographic Coronary Lesions (n=183).  
Characteristics Group 1 (n=98) Group 2 (n=85) 
p-value FA, B12 ±B6 Placebo or B6 
  
Demographic characteristics 
Age - years 59.3 (10.5) 61.5 (9.4) 0.14 
Female sex - no. (%) 17 (17.3) 12 (14.1) 0.69 
Clinical characteristics 
Systolic Blood Pressure (mmHg) 138.3 (20.7) 147.4 (23.9) 0.01 
Body Mass Index (m2/kg) 27.0 (3.2) 27.2 (3.5) 0.79 
Ejection Fraction (%a) 60.7 (7.4) 61.6 (9.2) 0.45 
Cardiovascular risk factors - no. (%) 
Stable angina at baseline angiography 67 (68.4) 59 (69.4) 0.88 
ACS at presentation 31 (31.6) 26 (30.6) 0.88 
Extracardial vascular diseaseb 7 (7.1) 15 (17.6) 0.03 
Prior AMI 24 (24.5) 26 (30.6) 0.36 
Prior PCI 22 (22.4) 12 (14.1) 0.15 
Prior CABG 5 (5.1) 1 (1.2) 0.14 
Hypercholesterolaemia 58 (59.2) 58 (68.2) 0.20 
Hypertension 40 (40.8) 40 (57.6) 0.40 
Diabetes Mellitus (type I and II) 7 (7.1) 10 (11.8) 0.28 
Current smoker 34 (34.7) 27 (31.8) 0.68 
Disease severity 0.90 
1-vessel disease 36 (36.7) 31 (36.5) 1.00 
2-vessel disease 41 (41.8) 38 (44.7) 0.77 
3-vessel disease 21 (21.4) 16 (18.8) 0.71 
Medical therapyc - no. (%) 
Statins 98 (100.0) 81 (95.2) 0.03 
ȕ-adrenergic receptor antagonists 82 (83.7) 57 (67.0) 0.01 
Calcium antagonists 18 (18.4) 11 (12.9) 0.32 
ACE-inhibitorsd 12 (12.2) 19 (22.4) 0.07 
Acetylsalisylic acid 96 (98.0) 85 (100.0) 0.19 
ADP receptor antagonists 92 (93.9) 79 (92.9) 0.80 
Laboratory findings 
S-C-Reactive Protein (mg/L) 1.8 (4.9) 2.5 (4.9) 0.40 
S-LDL cholesterol (mmol/L) 3.0 (1.3) 3.1 (1.1) 0.39 
S-HDL cholesterol (mmol/L) 1.2 (0.4) 1.2 (0.4) 0.76 
S-Apolipoprotein B100 (g/L) 0.87 (0.34) 0.88 (0.28) 0.33 
eGFR (mL/min/1.73 m2) 95 (17) 93 (19) 0.34 
S-glucose (mmol/L) 5.5 (1.3) 5.7 (1.7) 0.72 
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P-total homocysteine (ȝmol/L) 9.9 (3.1) 9.8 (3.3) 0.27 
P-folate (nmol/L) 10.1 (5.8) 11.0 (6.3) 0.20 
P-ADMA (ȝmol/L) 0.50 (0.09 0.52 (0.12) 0.23 
S-Trimethyllysine (ȝmol/L) 0.85 (0.34) 0.87 (0.40) 0.48 
S-Carnitine (ȝmol/L) 40.5 (7.5) 41.0 (10.1) 0.52 
S-Ȗ-Butyrobetaine (ȝmol/L) 0.98 (0.30) 1.02 (0.28) 0.05 
For continuous variables, mean and standard deviation or median and interquartile 
range within each group is calculated. Student's T-test or Mann-Whitney U-test was 
used to compare the two groups. For categorical variables, number and percentage is 
presented and a Chi square test was used to compare the four groups. Fisher's exact 
test was used when appropriate. All biochemical parameters are presented as median 
(interquartile range). FA, folic acid (0.8 mg); B12, vitamin B12 (0.4 mg); B6, vitamin B6 (40 
mg); PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft 
surgery; ACS, composite syndrome consisting of acute coronary syndrome including 
both ST-elevated and non-ST-elevated myocardial infarction; AMI, acute myocardial 
infarction; CHD, coronary heart disease; ACE, Angiotensin I converting enzyme; LDL, 
low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular 
filtration rate; ADMA, asymmetric dimethylarginine. Percentages may not add up due to 
rounding of numbers. 
a Ejection fraction was measured during ventriculography for the majority of the patients. 
When this was not performed, ultrasonic echocardiography was used. 
b A prior diagnosis of any peripheral or cerebrovascular disease. 
c Medication at discharge. 
d Including ARB - angiotensin receptor blockers. 
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4.4. The Association Between Progression of Atherosclerosis and the 
Methylated Amino Acids Asymmetric Dimethylarginine and 
Trimethyllysine (Paper II). 
PLoS ONE. 2013 May 29;8(5):e64774. 
A total of 309 coronary artery lesions as well as plasma levels of ADMA and TML were 
evaluated at both baseline and follow-up.  Using novel statistical methods, we showed 
that at follow-up median (95% CI) DS increased by 18.35 (5.22 – 31.49) percentage 
points per μmol/L ADMA increase (p-value 0.006) and 2.47 (0.37 – 4.58) percentage 
points per μmol/L TML increase (p-value 0.021) in multivariate modeling. Treatment 
with FA/B12 (±B6) was not associated with ADMA or TML levels. ADMA was 
independently associated with angiographic progression of CAD over a wide distribution 
of DS using a multivariate model – i.e. the adverse effect of elevated ADMA was similar 
in respect to both the effect estimate and level of significance across the 10th, 25th, 50th, 
75th and 90th percentile of DS. To our knowledge, neither ADMA nor TML has 
previously been shown to be associated with the progression of de novo atherosclerosis. 
To conclude, in patients with established CAD, baseline ADMA and TML was associated 
with angiographic progression of CAD. However, neither ADMA nor TML levels were 
altered by treatment with FA/B12 (±B6).  
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4.5. Effect of Folic Acid supplementation on Levels of Circulating Monocyte 
Chemoattractant Protein-1 and the Presence of Intravascular Ultrasound 
Derived Virtual Histology Thin-Cap Fibroatheromas in Patients with 
Stable Angina Pectoris (Paper III). 
 
PLoS ONE.  2013 July 25;8(7):e70101. 
In patients with CAD receiving established medical treatment and revascularization 
with PCI, we found no statistically significant association between treatment with folic 
acid/vitamin B12 and either levels of MCP-1 or the presence of occult VH-TCFA 
lesions by IVUS.  
 
Patients treated with folic acid/vitamin B12 had a geometric mean (SD) MCP-1 level of 
79.95 (1.49) versus 86.00 (1.43) pg/mL for patients receiving placebo (p-value 0.34), 
while VH-TCFA lesions were present in 7.8% of patients and did not differ between 
intervention arms (p-value 0.47).  We did however find a strong, statistically 
significant relationship between VH-TCFA lesions and elevated serum levels of MCP-
1. Serum levels of MCP-1 were 1.46 (95% CI 1.12 to 1.92) times higher in patients 
with VH-TCFA lesions than in those without (p-value 0.005). Additionally, in a post-
hoc analysis, MCP-1 levels predicted time to AMI in a Cox proportional hazard model 
with and without adjustment for established risk factors when followed for median 2.1 
years (P-value 0.006).  
 
To conclude, we showed that in patients with SAP receiving established medical 
treatment, folic acid / vitamin B12 supplementation is not associated with either 
presence of VH-TCFA or levels of MCP-1. MCP-1 is however associated with VH-
TCFA, a finding corroborated by increased risk for future AMI.  
 
54 
 
  
Figure 8. The chart shows the flow of patients from the WENBIT-trial (n=3090) to inclusion in 
the current IVUS-VH study (n=105).  
All patients were randomized to B-vitamin treatment at WENBIT-baseline. Of the 1359 patients who 
had PCI at WENBIT-baseline, 371 had new, scheduled angiography at the WENBIT-one year follow-
up. Of these 371 patients, 231 had received IVUS in a non-intervened vessel. IVUS-VH analysis and 
MCP-1 measurements were performed on 102 of these 231 patients and constituted our current 
study population. MCP-1 measurements were performed both at WENBIT-baseline (B-vitamin 
randomization) and at IVUS-VH study inclusion. Abbreviations are FA, folic acid (0.8 mg); B12, 
vitamin B12 (0.4 mg); B6, vitamin B6  (40 mg); WENBIT, Western Norway B-vitamin Intervention 
Trial; IVUS, intravascular ultrasound; IVUS-VH, intravascular ultrasound – virtual histology; PCI, 
Percutaneous coronary intervention and MCP-1, monocyte chemoattractant protein-1. 
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“By science calm’d over the peaceful soul, 
Bright with eternal wisdom’s lucid ray, 
Peace, meek of eye, extends her soft controul, 
And drives the fury passions far away.” 
 
Sir Humphry Davy (1778 – 1829). Excerpt from “Sons of Genius”. Robert Southey 
(ed) Annual Anthology vol.1 (Bristol 1799) pp 93-99. 
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5. DISCUSSION 
5.1. Summary 
This thesis is based on sub-studies from the Western Norway B-vitamin Intervention 
Trial (WENBIT) including patients undergoing both extensive and repeat invasive 
diagnostic procedures in order to measure rate of progression and (in)stability of CAD 
in a mostly unselected population of patients with SAP. WENBIT93 was one of several 
large-scale randomized clinical trials (RCTs) investigating the putative 
cardioprotective effects of homocysteine-lowering B-vitamin treatment launched 
during the early 2000s. While universally fruitless, a pattern of a possible detrimental 
effect in sub-groups started to emerge. The current thesis include studies where we 
investigated the effect of moderate dose folic acid and vitamin B12 intervention on the 
progression of coronary atherosclerosis, presence of unstable coronary plaques as well 
as circulating levels of two methylated amines, ADMA and TML and the 
inflammatory mediator MCP-1. This thesis adds to the current knowledge of 
progression of coronary atherosclerosis in patients with SAP. Specifically, that folic 
acid/vitamin B12 treatment is associated with rapid angiographic progression CAD in a 
sub-group of patients, but that this is not modulated by either unstable coronary lesions 
(TCFAs) or circulating levels of either, ADMA, TML or MCP-1. In addition we have 
shown that the methylated amines ADMA and TML are associated with progression of 
CAD and that the inflammatory marker and monocyte chemokine, MCP-1, is related 
to the presence of unstable coronary plaques and possibly future coronary events. 
 
5.2. Methodological discussion 
5.2.1. Study design and patient population 
Randomized, double-blinded placebo controlled trials (RCTs) are considered the gold 
standard of clinical investigation designed to minimize the implication of bias and 
human error130. WENBIT is to date the largest clinical RCT ever conducted in the 
western part of Norway and included patients undergoing coronary angiography for 
suspected CAD. A total of 3090 patients were randomized in a 2x2 factorial design in 
order to assess both folic acid/vitamin B12 vs. no folic acid/vitamin B12 and vitamin B6 
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vs. no vitamin B6 on incident cardiovascular events and mortality. Accordingly all sub-
studies included patients randomized in the same study design.  
 
Paper I and II conforms to a standard RCT design in which patients are randomized to 
treatment and followed for a period of time before primary end-points are acquired. 
Since patients recruited for this sub-study were subject to additional inclusion criteria 
following randomization, there exists a potential for selection bias which will be 
discussed further in the following section. In paper I we performed a sub-group 
analysis of patients with rapidly progressing atherosclerotic lesions which was 
performed outside of the a priori defined analyses. Introduction of such analyses 
always results in a risk of spurious findings, especially when the amount of baseline 
variables available for categorization is high, as in registry epidemiology and large-
scale RCTs131. Especially positive (or negative such as paper I in this thesis) trial 
results in a sub-group from an otherwise negative study should raise suspicion if 
overstated in the conclusion of a paper. However, within the framework of biological 
plausibility and supporting evidence they could provide enough evidence to formulate 
a purely hypothesis generating if interpreted with caution132. 
 
When inspecting the baseline data from the patients included in paper I and II, both in 
tables 2,3 and 4 it is readily apparent that randomization was largely successful and 
that there was no obvious distortion of covariates introduced by sub-study recruitment 
of patients. 
 
Paper III has a more complex study design which warrants some consideration. As 
outlined in figure 8, there are two follow-up time periods. Time period one from 
baseline and folic acid/B12 randomization with concomitant MCP-1 measurements 
until coronary angiography and VH-IVUS study inclusion with MCP-1 simultaneous 
measurements and time period two from VH-IVUS study inclusion until clinical 
follow-up for incident AMI (median 2.1 years) with no further MCP-1 measurements. 
The consequence of this is that sub-study recruitment was performed after, for most 
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patients, about 1 year of treatment with study medication. This in turn, potentially 
increases the risk of selection bias. 
 
5.2.2. Selection bias 
Selection bias is often used to refer to a number of different epidemiological biases, 
common of which all result in that the association between exposure and outcome 
differs between the selected patients and those eligible for analysis133. Of these, sample 
selection bias is probably the most well-known.  
 
While RCTs are considered well suited to minimize the impact of selection bias they 
are still subject to residual effects. Our patient population consisted of consecutively 
recruited patient referred to coronary angiography for suspected CAD and thus 
represents a rather non-selected cohort with mostly SAP. The consecutive approach to 
patient recruitment and only modest exclusion-criteria mainly pertaining to inability to 
comply with long-term follow-up is one of our major strengths.  
 
However, sub-studies performed within the WENBIT protocol presented in this thesis 
raises some concerns regarding sub-trial run-in. In both paper I and II progression of 
either CAD and/or biomarker activity, is measured in relation to the interventional 
regimen which in some instances already was started prior to patient inclusion. In 
WENBIT-RA some patients were recruited for sub-group inclusion (repeat 
angiography) at the 1 month control and sometimes later. While this allowed for the 
recruitment of more patients, it also potentially distorts the interpretation of the data. 
In paper I, where we investigate whether folic acid treatment accelerates CAD 
progression and did not find anything, we might also observe a “survivor” 
phenomenon. Those patients, either through genetic or environmental susceptibility, 
potentially adversely affected by FA might already have been excluded as they had 
already experienced their clinical event or that a putative “progression” had occurred 
and reached a new steady-state. This phenomenon has previously been attributed to 
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conflicting results of the association between hormone replacement therapy and CAD 
from observational versus randomized data134.  
 
For paper III, where sub-study recruitment was mainly conducted at the 1-year clinical 
follow-up/repeat angiography control, this especially holds true. While we did not 
detect a significant difference in either MCP-1 levels or VH-TCFA prevalence we 
cannot exclude a survivor-phenomenon wherein those susceptible to the potentially 
adverse FA effect would “never reach” the 1 year repeat angiography. With this in 
mind, one should be careful when concluding from the negative findings of paper III.  
 
5.2.3. Regression dilution bias 
Regression dilution bias is the statistical effect observable when a single measurement 
of a risk factor (e.g. blood pressure) is used instead of the “usual” level of the risk 
factor during the exposure time-frame. The unadjusted association between a risk 
factor and outcome is usually weaker than when a measurement over time or repeat 
measurements are used135. Risk estimates based on single measurements tend to 
underestimate the true effect of the observed relationship due to regression dilution 
bias. The intraclass correlation coefficient (ICC) of 0.54 for ADMA and 0.37 for TML 
in paper II are quite modest, as is the ICC of MCP-1 (from n=102) of 0.66. All 
implying that the “true” adverse effect of these parameters are, most probably, greater 
than apparent135. 
 
Statistical modeling allows for the use of repeat measurements for example through 
the application of mixed models such as those applied in paper I and II. Had this been 
applied to investigate risk assessment in paper II, one could potentially further unmask 
the underlying effect. However, in the setting of a placebo-controlled RCT this 
becomes difficult as one would have to include the treatment interaction as an 
interaction term, resulting in massive loss of statistical power. In addition 
interpretation and presentability of the results diminished with increasing model 
complexity. Accordingly this was not performed, although in hindsight it might have 
been prudent to do so. 
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5.2.4. Confounding 
Confounding is the statistical phenomenon wherein an apparent association between 
two observations is actually explained by a third, unknown factor – the confounder, 
which both observations are associated with. Numerous examples of such observed 
relationships that upon close scrutiny have been demonstrated to fall apart riddles the 
pages of medical history, some having endured for many decades. Several are easily 
apparent, while others are more subtle. 
 
Confounding is to a certain degree removed by controlling for the confounding factor 
in the analysis. In all analysis in papers I through III the multivariate analyses are 
controlled for a substantial number of factors, including not only obvious potential 
confounders such as age, sex and smoking, but more detailed information about 
coronary anatomy, ejection fraction and biochemical profiling. On the other end, 
adjustment for too many potential confounders results in loss of degrees of freedom 
and subsequently statistical power and model overfitting. In general, analyses in this 
thesis have been subject to a conservative approach with relatively liberal inclusion of 
potential confounders. I.e. the multivariate model in paper II includes 16 covariates 
from 183 patients.  
 
Can residual confounding explain the findings? Theoretically yes, although this would 
appear unlikely for a number of reasons. Regarding paper II, the fact that adjustment 
for a wide array of potential confounders resulted in a strengthening, rather than a 
weakening means that it is more likely a single, instead of multiple, residual 
confounder is the culprit. Secondly, it implies that the residual confounder would have 
to be unrelated to any of the included covariates. A completely unknown confounder 
for progression of CAD without any relationship with current established risk factors 
seems statistically unlikely. In paper III the relationship between TCFA presence and 
MCP-1 is strengthened in that MCP-1 (and VH-TCFAs) predicts AMI in the same 
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cohort – in a way a crude form of internal validation strongly implying that the 
observed relationship is true. 
 
5.2.5. Generalizability 
The concept of generalizability pertains to the ability of the data to make general 
inferences. All patients were recruited from WENBIT and were accordingly subject to 
WENBIT inclusion and exclusion criteria as outlined in the methods section. Broad 
inclusion criteria (patients aged 18 years or older referred to coronary angiography for 
suspected CAD) and few exclusion criteria (inability to comply with long-term follow-
up) results in a population pool of patients with established CAD which one could 
argue does not differ substantially from the “real-life” SAP patients, especially 
considering it in the framework of a RCT. The level of drop-out from WENBIT were 
modest, 456 (14.8%) stopped taking study treatment during follow-up of which 46 
(1.5%) were due to adverse effects93.  
 
The sub-study recruitment patient flow (figures 4 and 8) in this thesis is complicated. 
All patients were recruited at, or following, PCI during the sub-study recruitment 
period and were recruited in a non-selective manner. Meaning that all patients had 
angiographically verified CAD deemed suitable for invasive treatment. As shown in 
table 2, there is no major difference between those patients with and those without 
QCA-analyses performed, i.e. the patient cohort in paper I and II are representative of 
a mainly SAP cohort of patients with established 2- or the 3-vessel CAD. 
 
5.2.6. Spurious findings and multiple comparisons 
When performing multiple statistical analyses and comparisons there is always a risk 
for false positive findings. A significance level of 5% will result in 1 in 20 false 
positive findings when there is no real association present. This is a major cause for 
concern in the age of big data where access to registries with thousands of patients 
combined with thousands of measured variables results in millions of possible 
permutations and subsequently spurious findings.  
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In the post-hoc sub-group analysis of paper I, the fact that the observed relationship 
between FA/vitamin B12 and rapid progression was statistically significant only when 
applied to DS and end-points raises the question whether this was just a spurious 
finding. MLD and DS are both measures of the same phenomenon, luminal narrowing. 
However, DS is a relative measurement which is not subject to the potential calibration 
errors of MLDs absolute measurements. However, as a post-hoc finding it should be 
considered purely a hypothesis-generating finding.  
 
5.2.7. Visualization of plaque progression and stability 
QCA has been the standard for coronary visualization for several years and is by far 
the primary basis for both invasive and surgical treatment choices in CAD. However, 
inherent shortcomings are readily apparent. QCA is de facto a lumenogram, depicting 
the interior of the epicardial, coronary vessel. As the understanding of CAD 
progression and ACS broadens, so does our acknowledgement of the disease process 
within the vessel wall4, 25, 48. QCA has been shown to systematically underestimate the 
severity of mild stenoses136. For the visualization of these aspects of CAD, IVUS and 
optical coherence tomography (OCT) are much more suited. In addition, diffuse and 
complex luminal shapes such as thrombosis, dissection and ulcerations are not readily 
apparent with QCA. However, both IVUS and OCT are time- and cost-consuming in 
routine clinical practice. 
 
5.2.8. Biochemical considerations 
All blood samples were immediately frozen at -80°C by study personnel for storage, 
which could be considered adequate. Most standard blood analyses were performed by 
fresh samples at the Laboratory of Clinical Biochemistry, Haukeland University 
Hospital, which is a high-throughput, high-end institution.  B-vitamins and associated 
compounds were analyzed by Bevital, using previously described methods112 
developed by members of the extended research group and have been extensively 
validated, and for some compounds the only commercially (or scientifically) available 
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analysis platform. Plasma TML, free carnitine and Ȗ-butyrobetaine were also analysed 
using MS/MS as described previously113, as there were no other commercially 
available analysis platforms at the time. As paper III is to my knowledge one of the 
first studies wherein plasma TML have been measured in human subjects we have 
almost no way of comparing the observed values. It would be very interesting to 
analyse plasma TML in larger validation cohorts as well as in healthy/younger 
subjects. As TML is a direct product of proteolysis, it stands to reason that younger 
and healthier subjects might have higher baseline values due to an increased basal 
metabolic rate. MCP-1 was measured with established methods and presents no direct 
problems regarding interpretation. 

5.2.9. Statistical analysis 
Throughout this thesis we have employed some, at the time, novel and advanced 
statistical methods most of which have been extensively presented in the methods 
section. Especially the mixed-effects approach to linear modeling was at the time of 
publishing (paper I, 2010) quite uncommon in bio-medical literature. Since then 
however, mixed-model approaches have been applied in an almost exponential 
manner. The ability to model allow for “variation of variance” at different hierarchical 
levels is of obvious interest to investigators, but have previously been impossible due 
to both lack of methods and processing power, as well as availability of applicable 
software. Mixed effects modeling is now widely applied in meta-analyses, network 
analyses and observational/epidemiological work.  
 
Quantile regression, although used in the field of econometrics for several decades, is 
also rather new in biomedical research, also probably in part due to computational and 
technical requirements. We would argue that not only is it a more thorough and 
transparent analysis of outcome data, it is also inherently more suitable for the 
approach to biological systems were a non-parametric method is often the most 
conservative and reasonable option. 
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When applying novel, and/or under-utilized statistical methods, one could safely 
assume that there is an increased risk of software bugs, erroneous application or 
unintentional misinterpretation of data. This is natural in the biomedical sphere as few 
researchers have an extensive statistical and/or software development background. 
This is an inherent problem of “new methods” which we feel is an acceptable risk. It is 
however important to view such papers as more experimental than those applying 
more standardized methods. 
 
5.2.10. Inference of causality 
Casual inference refer to the process of determining the causality of a sequence of 
events from statistical data, that A causes B – i.e. concluding that in fact smoking 
causes lung cancer and is not only statistically associated with it. Causality in the 
setting of observational and epidemiological data is often more difficult to assess than 
one might intuitively think. Usually, complex multivariable adjusted models might 
reduce the risk of confounding to an acceptable level – but removing the possibility of 
reverse causality – that B causes A is within several methodological frameworks 
impossible. Correlation does not imply causation, as the mantra goes, effectively 
invalidating observational data as a source of causal inference. 
 
The framework of an RCT is arguably the best suited method for assessing causality in 
medicine. One could therefore propose that the observed relationship between folic 
acid supplementation and accelerated progression of CAD is causal – if confounding 
or spurious findings could have been ruled out. In both paper II and III, reverse 
causality – i.e. that plasma ADMA/TML and MCP-1 is elevated due to CAD 
progression or plaque instability respectively and not vice versa cannot be ruled out. 
Accordingly we have made no claims as to the direction of causality regarding these 
biomarkers, given the nature of these compounds – we would argue that it seems more 
probable that they, at least in the context of ADMA/TML are a bystander of disease 
state predisposing for CAD progression. In paper III, MCP-1 is a well-studied 
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chemokine intricately linked to the mechanistic understanding of plaque progression, 
making it difficult to rule out a causal relationship. 
 
More advanced methods of assessing causality in observational data include structural 
equation modeling (SEM), Mendelian randomization, graphical methods such as direct 
acyclic graphs (DAGs) and Bayesian networks have recently emerged in the 
biomedical field137. They are however advanced and time- and resource consuming. A 
SEM approach to paper III was initially explored but abandoned due to its complexity.  
 
5.2.11. Effect modification 
Effect medication, the phenomenon that the observed effect of an intervention differs 
across the strata of a third variable, is not to be confused with confounding 138. 
Technically, effect modification is not necessarily the same as interaction which is 
defined as the combined/synergetic effect of two interventions – although this is not 
mutually exclusive at all and is frequently assessed together. 
 
In all papers we have presented extensive baseline tables show only marginal 
differences between investigated groups. One of the main hypotheses of paper II was 
to investigate whether folic acid/vitamin B12 supplementation increased levels of 
ADMA/TML and whether this resulted in altered progression of CAD as assessed by 
QCA. Since no difference was found, we ruled out an effect modification between 
folic acid/vitamin B12 intervention and the relationship between ADMA/TML and 
QCA progression. Had we in fact shown such a relationship, an interaction term might 
have been added to the linear quantile model in order to test for interaction.  
 
5.2.12. Ethical considerations 
As previously stated all patients provided written, informed consent forms for both 
WENBIT and the WENBIT-RA sub-study. At the time of study conception there was 
no indication that folic acid/vitamin B12 supplementation would be detrimental – 
indeed grain fortification was and still is a world-wide, and in many regions 
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mandatory, phenomenon. The majority of the WENBIT-RA patients underwent an 
invasive coronary procedure without clinical indication – a potential harmful 
procedure. This was as previously stated approved by Regional Committee for 
Medical Research Ethics. The study protocol was in accordance with the principle of 
the Declarations of Helsinki. The study medication was approved by the Norwegian 
Medicines Agency and the data registration by the Data Inspectorate. 
 
5.3. Discussion of the main findings 
5.3.1. Study I: absence of a group effect and spurious findings 
Study I failed to find any effect of folic acid/vitamin B12 supplementation on CAD 
progression at the population-level102. In general post-hoc sub-group findings should 
be considered with extreme caution and only as hypothesis generating findings. 
However, the sub-group in paper I was not defined by a baseline characteristic, but by 
the primary end-point itself, DS. When isolating patients who were rapidly progressing 
– one could argue that it only aids in precipitating an effect which is obfuscated by 
statistical noise.  
 
A large body of evidence strongly suggests that the net effect of folic acid/vitamin B12 
supplementation on CVD is neutral83. However, strong sub-group heterogeneity and 
differing effects can create an apparent calm sea. In NORVIT, in the group given folic 
acid/vitamin B12 and vitamin B6 there was observed a trend toward an increased risk 
(relative risk, 1.22; 95 percent confidence interval, 1.00 to 1.50; P = 0.05) for the 
primary end-point of recurrent myocardial infarction, stroke, and sudden death 
attributed to CAD. On a similar note, post hoc analyses of WENBIT showed that there 
was an increased risk of the composite primary end point in the group receiving folic 
acid/vitamin B12 (HR, 1.34; 95% CI, 1.03-1.75; P=.03) compared with placebo. 
Combined results of NORVIT and WENBIT accordingly showed increased all-cause 
mortality95.  
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However, paper I showed a potential increase in angiographic progression and not 
clinical events. Interesting in this regard is a study by Lange et al. where the in-stent 
restenosis rate after PCI was higher in the folic acid group than in the placebo group 
(34.5% vs. 26.5%, P=0.05), and a higher percentage of patients in the folic acid group 
required repeated target-vessel revascularization (15.8% vs. 10.6%, P=0.05)139. While 
one can argue that the pathomechanisms for in-stent restenosis differs from de novo 
atherosclerosis, the apparent resemblance is intriguing. Lastly, a recent post-hoc 
analysis of the SU.FOL.OM3 study (Supplementation en Folates et en Oméga 3) by 
Blacher et al. looked at the effect of folic acid and omega 3 in a  2x2 factorial designed 
secondary CVD prevention study with regards to comparing the effect on hard 
coronary end-points and coronary revascularization140. In the study, treatment with 
folic acid or omega 3 did not increase the risk of coronary end-points, but folic 
acid/vitamin B12 and vitamin B6 supplementation (560 ȝg 5-tetrahydrofolate, 3 mg 
vitamin B6 and 20 ȝg vitamin B12) resulted in a statistically significant 52% increase in 
the rate of coronary revascularization (p = 0.0008). The link between angiographic 
progression and the need for repeat revascularization is obvious. Thus the study by 
Blacher et al. in many ways validates the findings of paper I and lends credence to the 
notion of a heterogenic effect of B vitamins. Future studies should more specifically 
evaluate if there are distinct sub-groups of patients that have clearly benefitted or be 
harmed by the B vitamin treatment. 
 
5.3.2. Study I: Potential adverse mechanisms 
Homocysteine may induce SMC proliferation141 and thusly provide a biologically 
plausible plaque-stabilizing effect142. Accordingly, it is not impossible that 
homocysteine-lowering vitamin B treatment would cause adverse effects in larger, 
lipid-rich and/or necrotic core lesions by directly leading to thinning of an already 
marginalized fibrous cap. Repeat plaque rupture is after all the most common cause for 
rapid plaque progression. Folic acid intervention could also potentially affect both cell 
proliferation and intracellular methylation status (discussed later). It is also relevant to 
note that substitution with folic acid does not necessarily lower intra-cellular 
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homocysteine even though plasma levels are affected. Possibly, folic acid impairs the 
regulation of methylenetetrahydrofolate reductase by S-adenosylmethionine143. 
 
5.3.3. Study I and II: Methylation status and folic acid supplementation 
The metabolic ramifications of folic acid supplementation are complex and have 
several potential adverse effects. Firstly, its effect on thymidine synthase promotes cell 
proliferation directly. This could potentially cause SMC proliferation and both 
concentric growth of the coronary plaque (causing angiographic progression, SAP and 
increased revascularization rates) while simultaneous provide plaque stabilization and 
no increase in clinical event rate. Secondly, the intracellular methylation potential is 
elevated with folic acid supplementation as the ratio of S-adenosylmethionine (SAM) 
to S-adenosylhomocysteine (SAH) increases. The enhanced methylation potential 
could have a host of adverse effects, including change in the expression of 
proatherogenic genes and increased production of ADMA72, 80. Both global and site-
specific hypo- and hypermethylation of DNA and histones are associated with CVD73, 
96 and high doses of folic acid induce aberrant DNA methylation in some 98 studies as 
has been hypothesized as a possible mechanism in which folic acid might prove 
deleterious to health80, 144. 
 
5.3.4. Study II: Methylated amines and methylation status 
Both ADMA and TML are methylated amino acids produced through proteolysis of 
methylated proteins. SAM is the global methylation donor for all intracellular 
methylation reactions. Increased SAM:SAH ratio and thus the intracellular 
methylation potential is necessarily linked with ADMA and TML – although the 
regulation of these metabolic steps is not well known. 
 
Research on the pathophysiology of ADMA is based mainly on impaired degradation 
as a source70. TML is produced in the same manner and is considered an obligatory 
by-product of global protein turnover. However, the degree to which post-translational 
methylation of amino acid residues is linked with global methylation potential is not 
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extensively explored145. It is interesting to note that both previous speculations72 and 
emerging evidence73-75 suggest that epigenetic alterations, including post-translational 
methylation of chromatin and histones is relevant to the development and progression 
of atherosclerosis.  
 
5.3.5. Study II: Lack of effect 
We found no effect of folic acid/vitamin B12 on the plasma levels of the circulation 
amino acids ADMA or TML146. While some studies have shown that 
supraphysiological doses of folic acid have led to increased DNA methylation98 in 
vitro and alter the SAM:SAH ratio in humans100, human studies have failed to 
demonstrate increased DNA methylation from folic acid supplementation99, 100, 147. 
DNA methylation and epigenetic regulations are extremely complex and tightly 
regulated processes73, 101, 148 and is probably not rate-limited by availability of methyl 
donors in an overly simplistic way148.  
 
However, 183 patients is a modest number and the lack of effect could possibly be 
explained by a lack of statistical power. A significant increase in the 10th percentile of 
ADMA in the group receiving folic acid/vitamin B12 does not necessarily reflect a 
spurious finding. When the statistical power is low and/or the effect modest, one 
would expect the result of the intervention to be most visible at the extreme ends of the 
Gaussian distribution – e.g. raising ADMA levels in those patients with the lowest 
values. That supplying methyl donors would result in a global increase of methylated 
amino acids in all patients is probably a far too simplistic approach. 
 
5.3.6. Study II: Prediction of CAD progression 
The link between ADMA, endothelial NOS inhibition, endothelial dysfunction and 
increased risk of CVD is well documented30, 31, 66, 67 and could fully explain the 
findings in our data were ADMA predicts progression of QCA146. While this has not 
been previously been demonstrated, it fits well with our current understanding of 
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progression of atherosclerosis in which endothelial dysfunction is pivotal in initiating 
and sustaining both inflammatory and fibroprolific activity1, 48. 
 
 
On the other hand, circulating TML as opposed to ADMA, has not been previously 
linked with CVD. Since TML is similar to ADMA in that it is a methylated amino acid 
residue produced through protein turnover – it is tempting to hypothesize that it works 
in a similar way – that is by inducing vascular dysfunction by inhibiting eNOS. This is 
however completely unsubstantiated by the current literature, although the list of NOS 
inhibitors is large149 and includes such compounds as L-N6-(1-Iminoethyl)lysine150. 
Testing of this hypothesis is however relatively straight forward and would provide 
much information.  
 
More intriguing however is TMLs role in carnitine metabolism, where it constitutes 
the first step human endogenous biosynthesis. Carnitine is involved in fatty acid 
metabolism71, 151, 152 and thus distortion in its biochemistry might represent 
mitochondrial (dys-)function. Mitochondrial dysfunction is emerging as a possible 
etiological and pathomechanistic explanation for a wide range of chronic diseases such 
as cancer153, diabetes154 and CVD155, 156. Carnitine metabolism is dependent upon 
mitochondrial function and circulating levels of carnitine and acyl-carnitines reflects 
impairment of fatty acid ȕ-oxidation157, 158. Since TML availability probably is the 
rate-dependent step in carnitine biosynthesis, or at least TML clearance152, 159, it is 
possible that mitochondrial dysfunction and impaired fatty acid metabolism results in 
an increase of TML as conversion to precursor Ȗ-butyrobetaine or carnitine is blocked. 
 
There is substantial co-linearity between TML, Ȗ-butyrobetaine, carnitine and kidney 
function146. Hypothetically, TML could act as a confounder for reduced renal function, 
Ȗ-butyrobetaine or carnitine which all possibly could be related to CVD risk – of 
which impaired kidney function is by far the best documented160. Estimated GFR was 
also significantly associated with progression of CAD in multivariate modeling. 
However, when we included eGFR in our multivariate models of TMLs effect on CAD 
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progression it did not substantially alter the effect of TML; suggesting that the 
observed association between TML and CAD progression is not confounded by kidney 
function.  
 
However, inclusion of Ȗ-butyrobetaine or carnitine in multivariate modeling did not 
alter TMLs predictive value and in addition, Ȗ-butyrobetaine or carnitine did not 
predict CAD progression in a separate analysis when TML was not included. Taken 
together, this could also suggest that TML has a causal relationship in CAD 
progression. If elevated TML represents impaired carnitine metabolism as an innocent 
bystander, one would possibly expect changes in other precursors in carnitine 
biosynthesis. 
 
5.3.7. Study III: Folic acid supplementation and plaque stability 
Repeated rupture and healing of unstable coronary plaques is an important mechanism 
in which atherosclerotic lesions progress in luminal narrowing – especially rapid 
progression161. The potentially adverse effect of FA administration could possibly be 
mediated through plaque destabilization and rapid progression of CAD in such a 
manner. We found nevertheless no statistical significant effect of folic acid/vitamin 
B12 on the presence of unstable coronary artery lesions as defined by the presence of 
VH-TCFA162. 
 
However, while repeated plaque ruptured is linked to rapid, angiographic progression 
of CAD it is also strongly associated with clinical events – after all, almost no 
coronary events happen without plaque rupture or erosion25. Accordingly, since the 
putative adverse effect of FA on CAD seems rather to result in angiographic 
progression102 and repeat vascularization140 as opposed to clinical event rates82 – it 
would appear plausible that FAs effect is mediated through a different mechanism than 
plaque destabilization. Consequently, one would perhaps expect the relationship 
between FA intervention and VH-TCFA presence to be either neutral or inverse. 
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5.3.8. Study III: MCP-1 and folic acid supplementation 
Previous studies have revealed an association between plasma homocysteine and 
MCP-1163, 164. In addition folic acid supplementation has shown to lower plasma MCP-
185, 163, 165. In paper III we were unable to reproduce these results in patients with 
SAP162 which we might have expected. These apparent discrepancies with the 
literature might reflect different study design and subjects characteristics, including the 
fact that plasma homocysteine at WENBIT baseline was relatively low (mean tHcy 
<10 ȝmol/L). Kim et al. reported a correlation of r = 0.31 (p <0.01) between plasma 
homocysteine and MCP-1164 which was not at all apparent amongst our patients, were 
the Spearman correlation coefficient between homocysteine and MCP-1 was r = 0.006.  
In addition, the fact that all patients had established CAD reflects a severity, both in 
time and extent, of the underlying pathological process that might conceivable negate 
the positive effect. Notably, the fact that most patients were under treatment with 
statins reflects a non-ignorable degree of anti-inflammatory treatment which could 
explain the abolished correlation between MCP-1 and homocysteine – and thus a 
biochemical state in which folic acid might provide an effect. Furthermore, Economou 
et al. showed that the correlation between homocysteine and MCP-1 is weakened by 
the presence of obesity and insulin resistance86. This however does probably not 
explain our negative findings, as stratifying according to BMI did not result in 
significant effects of folic acid/vitamin B12 treatment on MCP-1 levels in our material 
(data not shown).  
 
5.3.9. Study III: MCP-1 and plaque stability 
The primary focus of paper III was to investigate the effect of folic acid/vitamin B12 on 
plasma levels of MCP-1 and the presence of VH-TCFA. However, we also looked at 
the relationship between MCP-1 and the presence of VH-TCFA as well as prospective 
data on time to AMI. In previous studies, MCP-1 has been associated both with the 
presence of CAD risk factors in sub-clinical atherosclerosis57 and CVD mortality in 
middle-aged, obese patients 60. Moreover, in several studies by De Lemos et al. MCP-
1 is an independent predictor of death or myocardial infarction following an ACS 
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episode both in the acute setting and long-term follow up64, 65. While we had few 
patients and end-points, we were still able to replicate this relationship in our data set 
and showed that patients with elevated MCP-1were significantly higher at risk for 
experiencing an AMI during 2.1 years of follow-up, both in uni- and multivariate Cox 
proportional hazard models adjusted for common risk factors.  
 
Regarding VH-TCFAs, we found that MCP-1 levels were linked to the presence of 
VH-TCFA lesions. Specifically, that patients with VH-TCFA had 46% higher plasma 
MCP-1. Moreover, 25% of patients in our study with VH-TCFA experienced a 
coronary event within 2.1 years of follow-up. The last observation is in accordance 
with the findings of the Providing Regional Observations to Study Predictors of Events 
in the Coronary Tree (PROSPECT) trial by Stone et al. which validated the predictive 
value of VH-TCFA lesions on coronary end-points in a prospective manner109. 
 
Finding from the literature suggest that TCFA-lesions are present in as much as two-
thirds of culprit lesions19, 166, 167. A prerequisite for the development of such a lesion is 
monocyte infiltration, in which MCP-1 plays an pivotal role54 55, 56. MCP-1 is 
necessary  for trans-endothelial migration 52 and regulation of macrophage activity54, 
55, both considered a sine qua non of the destabilization of coronary atherosclerotic 
plaques4, 53. 
 
Accordingly it is not biologically implausible that the ability of MCP-1 to predict 
coronary events observed by De Lemos and others is a result of the potential 
association between MCP-1 and the presence of VH-TCFA lesions which we observed 
in paper III. Raised circulating levels of MCP-1 might represent increased monocyte 
recruitment, a necessary step on the ladder towards the formation of VH-TCFA lesions 
– which in itself are associated with adverse coronary events. To support this 
hypothesis, recent work by Li et al. showed that MCP-1 levels and mRNA expression 
is associated with ACS and plaque rupture168. The strength of the post-hoc findings in 
paper III is that we are able to demonstrate a statistically significant association 
between MCP-1, VH-TCFA and future AMI. In a way this is a form of internal 
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validation of the hypothesis that MCP-1 predicts the presence of high-risk coronary 
lesions. 
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6. CONCLUSION 
The studies included in the present thesis aimed to investigate the effect of folic acid 
and vitamin B12 supplementation on progression of sub-clinical CAD in patients with 
mostly SAP as well as metabolites related to potential mechanisms of progression. In 
conclusion, the present thesis found the following answers to the study aims: 
 
6.1. Study I: Homocysteine-lowering folic acid/vitamin B12 treatment during median 
10 months demonstrated no protective effect on the progression of CAD as 
expressed by MLD and DS measured by repeat QCA. Moreover, a possible 
adverse effect by this treatment promoting rapid progression of larger and bulkier 
lesions was indicated in post-hoc analysis.  
 
6.2. Study II: ADMA and TML were associated with angiographic progression of 
CAD. However, treatment with folic acid/vitamin B12 did not alter the plasma 
levels of either ADMA or TML. The possible adverse of folic acid/vitamin B12 on 
CAD progression is most likely unrelated to the metabolism of methylated amino 
acids.  
 
6.3. Study III: Folic acid/vitamin B12 supplementation did not alter either 
MCP-1 levels or the presence of occult VH-TCFA coronary lesions in SAP 
patients. However, MCP-1 was associated with the presence of VH-TCFA 
lesions and both were associated with future AMI as well as with each other. 
The possible adverse of folic acid/vitamin B12 on CAD progression is most 
likely unrelated to plaque instability and repeated rupture. In addition MCP-1 
could be used to select SAP patients for further investigations, including VH–
IVUS, to identify patients with VH-TCFA lesions.  
 
In conclusion our findings support the notion that treatment with folic acid/vitamin B12 as 
secondary prevention in CAD patients is not warranted and may increase progression of 
CAD in subsets of patients. 
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FUTURE PERSPECTIVES 
 
We are currently evaluating the effect of the B-vitamin therapy in WENBIT according to 
selected genotypes within one-carbon metabolism, and preliminary data strongly support 
that folic acid supplementation is a double-edged sword with detrimental effects 
according to genotype. Studies replicating our possible findings will be needed, and 
several such studies are planned. The mechanism in which folic acid might provide 
progression of angiographic CAD and the need for coronary revascularization without 
increase in mortality is yet to be elucidated. 
 
On a side note, further investigation should also aim to identify (lifestyle) determinants of 
plasma TML. Circulating TML levels have a short track-record in the scientific literature 
and provide a new frontier as a metabolic compound from the nexus of several inter-
connecting processes such as methylation, carnitine and fatty acid metabolism and 
mitochondrial dysfunction. A recent paper by Koeth et al. published in Nature showed 
that plasma L-carnitine levels in subjects undergoing cardiac evaluation predicted 
increased risks for both prevalent CVD and incident major adverse cardiovascular events, 
but only among subjects with concurrently high trimethylamine-N-oxide levels169. 
Whether carnitine in this setting is a confounder for the precursor, TML is a very 
interesting question. A prospective study on TMLs effect on cardiovascular end-points is 
currently under way. 
 
In regards to MCP-1, it would be interesting to confirm the association between 
vulnerable plaques and levels of MCP-1 and whether MCP-1 measurement could be used 
to select SAP patients which are at higher risk for future coronary events and have 
unstable coronary lesions amendable by PCI.  
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